

Review



# The Genus *Cuphea* P. Browne as a Source of Biologically Active Phytochemicals for Pharmaceutical Application and Beyond— A Review

Danuta Sobolewska<sup>1</sup>, Klaudia Michalska<sup>2</sup>, Dagmara Wróbel-Biedrawa<sup>1</sup>, Karolina Grabowska<sup>1</sup>, Aleksandra Owczarek-Januszkiewicz<sup>3</sup>, Monika Anna Olszewska<sup>3,\*</sup> and Irma Podolak<sup>1</sup>

- <sup>1</sup> Department of Pharmacognosy, Medical College, Jagiellonian University, 30-688 Kraków, Poland
- <sup>2</sup> Department of Phytochemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, 31-343 Kraków, Poland
  - <sup>3</sup> Department of Pharmacognosy, Faculty of Pharmacy, Medical University of Lodz, 90-151 Lodz, Poland
  - \* Correspondence: monika.olszewska@umed.lodz.pl

**Abstract:** *Cuphea* P. Browne (Lythraceae) is a monophyletic taxon comprising some 240–260 species that grow wild in the warm, temperate, and tropical regions of South and Central America and the southern part of North America. They have been valued as traditional medicinal remedies for numerous indications, including treating wounds, parasitic infections, hypertension, digestive disorders, cough, rheumatism, and pain. Modern pharmacological research provides data that support many of these traditional uses. Such a wide array of medicinal applications may be due to the exceptionally rich phytochemical profile of these plants, which includes bioactive compounds classified into various metabolite groups, such as polyphenols, triterpenes, alkaloids, and coumarins. Furthermore, *Cuphea* seed oils, containing medium-chain fatty acids, are of increasing interest in various industries as potential substitutes for coconut and palm oils. This review aims to summarize the results of phytochemical and pharmacological studies on *Cuphea* plants, with a particular focus on the therapeutic potential and molecular mechanisms of the action of polyphenolic compounds (especially flavonoids and tannins), which have been the subject of many recently published articles.

Keywords: Cuphea; pharmacological activity; phytochemistry; natural products; traditional use

# 1. Introduction

*Cuphea* P. Browne is an endemic American genus, the largest of the Lythraceae family [1,2]. This monophyletic taxon comprises approximately 240–260 species that grow wild in temperate, subtropical, and tropical regions [3,4]. The *Cuphea* genus is divided into two subgenera and 13 sections:

- subgenus *Cuphea* Koehne (*Lythrocuphea* Koehne); sections: *Archocuphea* Koehne, *Cuphea*;
- subgenus Bracteolatae S.A.Graham (Eucuphea Koehne); sections: Amazoniana
   Lourteig, Brachyandra Koehne, Diploptychia Koehne, Euandra Koehne, Heteranthus
   Koehne, Heterodon Koehne, Leptocalyx Koehne, Melicyathium Koehne, Melvilla
   Koehne, Pseudocircaea Koehne, Trispermum Koehne [3,5].

The most numerous section is *Euandra* Koehne, which includes about 60 species [6]. *Cuphea* plants are native to South and Central America and the southern part of North America (southeastern USA; western and southern mountains of Mexico). Most species grow in Brazil, and 69 of the total 108 Brazilian species are endemics [7]. An exceptionally high diversity and abundance of *Cupheas* is observed in Brazilian cerrados and savannas in Bahia, Goiás, and Minas Gerais [6,8]. They grow in natural sites up to an altitude of

Citation: Sobolewska, D.; Michalska, K.; Wróbel-Biedrawa, D.; Grabowska, K.; Owczarek-Januszkiewicz, A.; Olszewska, M.A.; Podolak, I. The Genus *Cuphea* P. Browne as a Source of Biologically Active Phytochemicals for Pharmaceutical Application and Beyond—A Review. *Int. J. Mol. Sci.* 2023, 24, 6614. https:// doi.org/10.3390/ijms24076614

Academic Editor: William N. Setzer

Received: 14 February 2023 Revised: 22 March 2023 Accepted: 29 March 2023 Published: 1 April 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). 3.000 m above sea level, usually in roadside, open, moist, mesophytic areas and pastures [1,9]. Some species have been introduced to Africa and Southeast Asia [10,11]. In some countries they are classified as invasive plants; e.g., *C. ignea* A.DC. in La Réunion [12,13]. On the other hand, in 2018, *C. melvilla* Lindl. was listed on the IUCN Red List of Threatened Species, although it is listed under the heading "least concern". It should be noted that several *Cuphea* species (*C. glutinosa* Cham. & Schltdl. and *C. ignea* A.DC. as examples) are cultivated as landscape and ornamental plants in gardens and can also be grown in-doors [14,15].

*Cuphea* plants are widely used in traditional South American and Mexican medicine as anti-inflammatory, diuretic, antipyretic, antimicrobial, astringent, and hypotensive agents. Herbal teas, infusions, or decoctions are the most widespread traditional preparations, and are most often prepared from the aerial parts [16–18]. To date, only about a dozen species have been studied for their pharmacological activity. However, given their therapeutic potential and prospects for development, some of them have already attracted considerable interest as potential phytopharmaceuticals. These include, for example, *C. aequipetala* Cav., *C. calophylla* Cham. & Schltdl., *C. carthagenensis* (Jacq.) J.F.Macbr., *C. glutinosa* Cham. & Schltdl, *C. ignea* A.DC., and *C. pinetorum* Benth. However, no clinical trials evaluating their efficacy have been conducted to date.

Most plants of the genus *Cuphea* are valuable industrial oil crops due to their ability to synthesize medium-chain fatty acids (MCFAs), including caprylic (C8:0), capric (C10:0), lauric (C12:0), and myristic (C14:0) acids, which are stored in the seeds. Therefore, *Cupheas* are considered as potential replacements for currently exploited industrial sources of MCFA's, such as *Cocos nucifera* L. (coconut) and *Elaeis guineensis* Jacq. (palm kernel) [19,20].

For this reason, much attention has recently been given to the domestication of *Cupheas* suitable for large-scale cultivation [19]. However, this is not an easy task due to several characteristics typical of non-domesticated species that limit their agricultural suitability, such as an indeterminate pattern of continuous flowering, a hard seed coat and consequent dormancy, early seed shedding and shattering from maturing fruits, glandular trichomes on stems, and floral tubes that produce sticky/resinous substances [19,21]. For example, shattering of seed pods can lead to significant, almost 100%, seed loss [22]. Furthermore, many *Cuphea* species are entomophilous plants that attract bees or butterflies, which is another factor limiting their commercial production [23]. One of the recently explored ways to overcome this problem is the search for suitable pollinators to increase plant seed production. It appears that the subgenus *Heterodon* may provide the best candidates for agronomic crops due to its larger seeds, extremely abundant inflorescences, and considerable height [24].

Several successful attempts have been made to develop commercial *Cuphea* lines. To this end, the cultivar PSR23 (Partial Shatter Reduction line No. 23; PI606544, released by Knapp and Crane) was obtained through interspecific hybridization of *Cuphea viscosissima* Jacq. and *C. lanceolata, f. silenoides* W.T.Aiton as a potential feedstock for biodiesel production [25,26]. The term "partial seed reduction" stands for the fact that the seed capsules of line No. 23 do not split and spread as readily as those of other *Cuphea* lines. *Cuphea* PSR23 was the first cultivar in which seed loss was reduced to 20–30%, while having high oil content and non-dormant seeds [22].

Some *Cuphea* species are rich in polyphenols and can be considered as convenient sources of natural antioxidants in industrial processes [27]. For this reason, polyphenols are the most studied group of *Cuphea* phytoconstituents.

# 2. Botanical Characteristics

The name Cuphea comes from Greek  $\kappa \upsilon \varphi \delta \zeta$ , meaning stooping, bent forward, or hunched back [28]. The term probably refers to the shape of the fruiting capsule. In the Spanish-speaking world, Cuphea plants are also known by the generic name sete-sangrias (seven bleedings). They represent summer annual and perennial herbaceous plants or semi-shrubs that grow up to 2 m; however, most Cupheas are less than 1.5 m [1].

Cuphea species typically produce simple leaves with thin leaf blades, the arrangements of which are opposite or verticillate. In most species, the size of the leaf gradually decreases toward the top of the plant. Solitary flowers develop at the leaf nodes, forming raceme inflorescences. The flowers are hexamerous and zygomorphic, with an elongated tubular calyx terminated with six deltate petals, which are often small or vestigial [1,7]. The predominant flower color is purple (e.g., C. lanceolata W.T.Aiton) to red (e.g., C. nudicostata Hemsl.), although some rare examples may develop yellow flowers (e.g., C. xanthopetala S.A.Graham & T.B.Cavalc.) or bicolored floral tubes, e.g., C. annulata Koehne, C. cyanea Moc. & Sessé ex DC., and C. spectabilis S.A. Graham. Leaves, stems, and flowers are covered with sticky and glandular hair [2,3,29,30]. A couple of characteristics distinguish the genus from other members of the Lythraceae family: interpetiolar emergence of flowers, and the "disc" – a free-standing nectiferous organ at the base of the ovary. Other morphological synapomorphies include 11 stamens (rarely less), oblate pollen, and a unique seed dispersal mechanism [2,3]. Seeds are flattened and biconvex, with inverted, spiral, mucilaginous trichomes. They are attached through coordinated slits in the dorsal wall of the capsule and in the floral tube. A placenta exserted from the capsule allows seed dispersal.

One of the most important factors determining Cuphea seed production is temperature. Seed yields are reduced under hot and dry conditions. Seed production of the PSR23 cultivar is better adapted to cool and temperate climates and depends mainly on high water use [31,32]. Warm to hot weather conditions with sufficient humidity are optimal for vegetative growth of wild Cuphea species [9]. However, the vegetative biomass production of the PSR23 cultivar is not strictly dependent on temperature.

Storage temperature is one of the most important factors affecting seed viability, but its effect depends on the fatty acid composition of the triacylglycerols in individual Cuphea oils. In the case of a high concentration of lauric and/or myristic acids in the oil, a loss of viability can be observed when seeds are stored at -18 °C [33]. Seeds with a high content of capric, caprylic, or unsaturated fatty acids can withstand exposure to low temperatures much better.

#### 3. Phytochemistry

#### 3.1. Cuphea Seed Oil and Fatty Acids

As mentioned above, Cuphea plants are a rich source of MCFAs. About 50% of the species produce lauric acid, which is the predominant fatty acid in South American Cupheas, while oils from North American species are more diverse [34]. The average oil content of wild Cupheas seeds ranges from 30 to 35%, while the oil content in the seeds of PSR23 ranges from about 27 to 33% [35,36]. Seeds of the PSR23 cultivar were found to contain 4–5% more oil than the wild parents (C. lanceolata W.T.Aiton and C. viscosissima Jacq.) [37]. Furthermore, oil production in this variety may increase with increasing latitude.

There are several techniques for extracting oil from Cuphea seeds [38]. Standard procedure involves solvent extraction or mechanical extraction by screw pressing. The first method is more efficient, but exposure to solvents can be hazardous to workers and the environment. Screw pressing can extract only about 80% of the oil from the seeds [39]. The crude oil obtained by both methods must be properly refined by bleaching and deodorization (RBD). The undesirable high chlorophyll content in oil obtained by screw pressing can be reduced by dehulling Cuphea seeds prior to extraction [40]. Supercritical carbon dioxide (SC-CO2) extraction yields high-quality Cuphea seed oil with a much lower free fatty acid content and higher brightness than Cuphea oil obtained by RBD following solvent extraction [38]. Thus, this method is an economically viable alternative. Some Cuphea oils can be relatively homogeneous and contain glycerides of a single fatty acid [33]. For example, C. wrightii A.Gray oil is rich in lauric acid (72,8%), C. llavea Lex. oil accumulates high levels of capric acid (92%) [41], while PSR23 oil contains a high amount of decanoic acid (65–73%), and its levels are generally greater in northern growing regions compared to southern ones [26,36]. On the other hand, longer-chain fatty acids predominate in some other species. For example, linoleic acid (18:2) is the main component of the seed oil of C. lindmaniana Koehne ex Bacig. and C. flavovirens S.A.Graham [42].

Table 1 lists Cuphea species according to the predominant fatty acid in the oil.

Dominant Fatty Acid	Cuphea Species	Total Fatty Acid Content in Oil (%)	Dominant Fatty Acid	Cuphea Species	Total Fatty Acid Content in Oil (%)
Caprylic (C8:0)	C. avigera var. pulcherrima (R.C.Foster) S.A.Graham	75–94	Lauric (C12:0)	C. laminuligera Koehne	63; 52–60 ***
	C. cordata Ruiz & Pav.	50		C. lobophora Koehne	66
	C. cyanea Moc. & Sessé	68		C. lutea Rose ex Koehne	38; 34–42 ***
	C. hookeriana Walp.	50		C. lutescens Pohl ex Koehne	66; 76; 66 *
	C. painteri Rose ex Koehne	65		<i>C. melanium</i> (L.) R.Br. ex Steud.	77; 86
	C. pinetorum Benth.	48	_	C. melvilla Lindl.	46; 52
Capric (C10:0)	<i>C. angustifolia</i> Jacq. ex Koehne	67–80		C. micrantha Kunth	43; 53
	<i>C. avigera</i> B.L.Rob. & Seaton	43		<i>C. parsonsia</i> (L.) R.Br. ex Steud.	74; 63 ***
	C. bustamanta Lex.	63		C. pohlii Lourteig	44
	C. caesariata S.A.Graham	86		C. polymorphoides Koehne	80
	C. calaminthifolia Schltdl.	44; 44 *		C. pseudovaccinium A.St Hil.	69; 83
	C. calcarata Benth.	64		C. pulchra Moric.	56
	C. cordata Ruiz & Pav.	50		C. retroscabra S.Watson	55
	C. crassiflora S.A.Graham	87		<i>C. rupestris</i> T.B.Cavalc. & S.A.Graham	54
	C. ferrisiae Bacig.	82; 82 *		C. sclerophylla Koehne	60; 67
	C. hookeriana Walp.	50		C. sessiliflora A.StHil.	64; 37 *
	C. humifusa S.A.Graham	82		C. setosa Koehne	62
	C. ignea A.DC.	87; 54 ****		C. sincorana T.B.Cavalc.	39
	C. inflata S.A.Graham	86		C. spermacoce A.StHil.	49
	C. koehneana Rose	92: 92 *		C. splendida Lourteig	51
	C. lanceolata W.T.Aiton	83; 78–91 ***		C. strigulosa Kunth	53 **
	C leptopoda Hemsl.	87		C. teleandra Lourteig	71
	C. llavea Lex.	86; 88; 83 ***; 92 ***		C. tolucana Peyr.	53; 46–64 ***
	C. lophostoma Koehne	62; 81		C. trochilus S.A.Graham	62; 62 *
	C. micropetala Kunth	26		C. thymoides Cham. & Schltdl.	56; 65
	C. nitidula Kunth	74		<i>C. tuberosa</i> Cham. & Schltdl.	56
	C. paucipetala S.A.Graham	87		C. urbaniana Koehne	48
	C. procumbens Ortega	80; 82; 81–89 ***		C. urens Koehne	76
	C. quaternata Bacig.	63; 63 *		C. vesiculigera R.C.Foster	71; 71 *
	C. schumannii Koehne	94		C. viscosa Rose ex Koehne	60; 60 *
	C. viscosissima Jacq.	76; 76 *	_	C. wrightii A.Gray	54; 54 **
Lauric (C12:0)	C. acinifolia A.StHil.	65		C. wrightii var. wrightii	58-73 ***
	C. acinos A.StHil.	64	Myristic (C14:0)	C. aequipetala Cav.	56
	C. adenophylla T.B.Cavalc.	73		C. epilobiifolia Koehne	55; 55 *
	<i>C. appendiculata</i> Benth.	73; 83; 83 *		C. palustris Koehne	64; 71


Table 1. Percentage of the predominant fatty acid content in oils of different Cuphea species.

<i>C. bahiensis</i> (Lourteig) S.A.Graham & T.B.Cavalc.	47		C. rasilis S.A.Graham	49
<i>C. brachiata</i> Mart. ex Koehne	47		<i>C. salvadorensis</i> (Standl.) Standl.	65
<i>C. brachypoda</i> T.B.Cavalc.	47		<i>C. sessiifolia</i> Mart.	37
<i>C. calophylla</i> Cham. & Schltdl.	62–85; 85 *; 56–65 ***		<i>C. strigulosa</i> subsp. <i>nitens</i> Koehne	37
C. calophylla subsp. calophylla	58-72 ***		C. strigulosa subsp. opaca Koehne	45; 45 *
C. calophylla subsp. mesoste- mon (Koehne) Lourteig	59–70 ***		C. tetrapetala Koehne	51
C. carthagenensis (Jacq.) J.F.Macbr.	61; 81; 59 **; 59–67 ***	Oleic (C18:1)	C. circaeoides Sm. ex Sims	48
C. confertiflora A.StHil.	73		C. denticulata Koehne	53
C. diosmifolia A.StHil.	64	Linoleic (C18:2)	C. decandra Dryand.	45
C. egleri Lourteig	57		C. flavovirens S.A.Graham	23; 23 *
<i>C. ericoides</i> Cham. & Schltdl.	43		C. fruticosa Spreng.	67
C. ferrisiae Bacig.	35		C. linarioides Cham. & Schltdl.	34–62
<i>C. ferruginea</i> Pohl ex Koehne	55		<i>C. lindmaniana</i> Koehne ex Bacig.	55; 55 *
C. flava Spreng.	43		C. linifolia Koehne	49; 63
C. gardneri Koehne	68		<i>C. mimuloides</i> Schltdl. & Cham.	30
C. glareosa T.B.Cavalc.	49		<i>C. pascuorum</i> Mart. ex Koehne	53
C. glossostoma Koehne	58 ***		C. purpurascens Bacig.	36; 36 *
<i>C. glutinosa</i> Cham. & Schltdl.	50; 82; 54 ***		C. subuligera Koehne	29
<i>C. grandiflora</i> Pohl ex Koehne	62		C. utriculosa Koehne	31
C. heterophylla Benth.	48; 42 ***	Linolenic (C18:3)	C. spectabilis	31; 31 *
C. hyssopifolia Kunth	79			
C. ingrata Cham. & Schltdl.				
<i>C. jorullensis</i> Kunth	53; 53 *			LY [ 4 1 ] YYYY [ 40]


The table was compiled on the basis of the data reported in: [34]; \* [42]; \*\* [20]; \*\*\* [41]; \*\*\*\* [43].

# 3.2. Polyphenols


Many recent reports on Cuphea phytochemistry have been devoted to the characterization of various phenolic fractions: flavonoids (Figure 1), phenolic acids and their derivatives (Figure 2), tannins (Figure 3) and stilbenes (Figure 4) [44]. Quercetin glycosides have been identified as major flavonoids, along with other flavonols: rhamnetin, isorhamnetin, and kaempferol; flavones: apigenin, and luteolin; isoflavone genistein; and their glycosides [45–49]. Sugar residues generally include galactose, glucose, rhamnose, arabinose, xylose, and glucuronic acid. In addition, the rare quercetin 3-sulfate has been identified in an aqueous extract of the aboveground parts of *C. carthagenensis* (Jacq.) J.F.Macbr. and a methanolic extract of *C. ingrata* Cham. & Schltdl. [47,50]. In addition to flavonoids, another class of polyphenols, the macrocyclic tannins, has received particular attention, among which the dimeric ellagitannins (cuphiin D<sub>1</sub>, cuphiin D<sub>2</sub>, oenothein B, and woodfordin) are of great interest due to their anticancer properties [51].



	R	R <sub>1</sub>	$\mathbf{R}_2$	$R_3$
Quercetin	Н	Н	Н	Η
Quercetin-3-O-arabinoside	Ara	н	н	Н
Quercetin-3-O-glucoside	Glc	н	н	Н
Quercetin-3-O-rhamnoside	Rha	Н	Н	Η
Quercetin-3-O-glucuronide	Gluc	Н	Η	Η
Quercetin-3-O-galactoside	Gal	н	н	Η
Quercetin-3,7-O-diglucoside	Glc	н	Glc	н
Quercetin-3-O-rhamnosylglucoside	Rha-Glc	н	н	Н
Quercetin-3-O-galactosylgalactoside	Gal-Gal	Η	Η	Η
Quercetin-3-O-(galactose-rhamnose)	Gal-Rha	н	н	Η
Quercetin-3-O-(galactose-glucose)	Gal-Glc	н	н	н
Quercetin-3-O-(galactose-glucuronic acid)	Gal-Gluc	н	н	Н
Quercetin-3-(2-galloylglucoside)	Gall-Glc	Н	Н	Η
Quercetin-3-O-arabinofuranoside	Arb-F	Н	Н	Η
Quercetin-3-O-(arabinose-glucose)	Arb-Glc	Н	Н	Η
Quercetin-3-O-galloyl rhamnoside	Gall-Rha	н	н	н
Quercetin-3-O-(glucose-rhamnose)	Glc-Rha	н	н	Η
Quercetin-3-O-(glucose-glucuronic acid)	Glc-Gluc	Η	Н	Η
Quercetin-3-O-glucosyl-glucoside	Glc-Glc	н	н	Н
Quercetin-3-O-glucosyl-glucosyl-glucoside	Glc-Glc-Glc	н	н	н
Quercetin-3-O-acetyl-glucuronide	Ac-Gluc	н	н	Н
Quercetin-3-O-malonylglucoside	Malo-Glc	Н	н	Η
Quercetin-3-O-(4"-malonylrhamnoside)	Malo-Rha	Η	Н	Η
Quercetin-3-O-β-D-glucuronide butyl ester	Gluc-Bu	н	н	н
Quercetin-3-O-sulfate	$SO_3H$	н	н	Н
Quercetin-4'-O-galactoside	Н	Н	Η	Gal
Quercetin-5-O-β-glucoside	Н	Glc	Н	Η



	R	$R_1$
Kaempferol	Н	н
Kaempferol-3-O-xyloside	Xyl	Н
Kaempferol-7-O-rhamnoside	Ĥ	Rha
Kaempferol-3-O-glucoside	Glc	Н
Kaempferol-3-O-rutinoside	Rut	Η
Kaempferol-3-O-galactoside	Gal	Н
Kaempferol 3-O-glucuronide	Gluc	Н
Kaempferol-3-O-galloyl-glucoside	Gall-Glc	Н
Kaempferol-3-O-(glucose-rhamnose)	Glc-Rha	Н
Kaempferol-3-O-(rhamnose-glucoside)	Rha-Glc	Н
Kaempferol-3,7-O-dirhamnoside	Rha	Rha



	R
Myricetin	Н
Myricetin-3-O-glucoside	Glc
Myricetin-3-O-rhamnoside	Rha
Myricetin-3-O-arabinoside	Arb
Myricetin-3-O-galactoside	Gal
Myricetin-3-O-glucuronide	Gluc
Myricetin-3-O-xyloside	Xyl
Myricetin-3-O-arabinosyl-arabinoside	Arb-Arb
Myricetin-3-O-(arabinose-galactose)	Arb-Gal
Myricetin-3-O-(glucose-rhamnose)	Glc-Rha
Myricetin-3-O-(2-galloyl-glucoside)	2-Gall-Glc
Myricetin-3-O-galactosyl-galactosyl-galactoside	Gal-Gal-Gal




Figure 1. Chemical structures of flavonoids and their derivatives of the genus Cuphea.




Figure 2. Chemical structures of phenolic acids and their derivatives of the genus Cuphea.




Figure 3. Chemical structures of tannins of the genus Cuphea.




Figure 4. Chemical structures of stilbenes of the genus Cuphea.

Most quantitative studies on *Cuphea* polyphenols provide data on the determination of total phenolic content (TPC) and total flavonoid content in extracts and fractions, usually calculated as gallic acid equivalents (GAE) and quercetin equivalents (QE), respectively. The results obtained by different authors vary considerably; these differences are mainly due to the study of different species and different parts of the plants as well as the use of different extraction solvents. For example, Krepsky et al. [45] observed a significant solvent-dependent effect when analyzing the phenolic content of different fractions of the ethanolic extract from aerial parts of C. carthagenensis (Jacq.) J.F.Macbr. The ethanolic extract, after concentration, was suspended in water and then sequentially extracted with *n*hexane, dichloromethane, ethyl acetate, and n-butanol. The aqueous part was divided into methanol-soluble and methanol-insoluble fractions. The highest content of phenols and tannins, expressed as percentage of dry material, w/w, was determined in the *n*-butanol fraction ( $87.6 \pm 4.2\%$  and  $75.0 \pm 0.9\%$ , respectively). The emulsion formed during the partition of the ethanol extract with dichloromethane contained the highest level of proanthocyanidins ( $37.90 \pm 0.50\%$ ) and flavonoids ( $5.80 \pm 0.16\%$ ) [45]. More recently, Rather et al. [17] estimated the total phenolic and flavonoid content of a methanolic extract from leaves of the same species (*C. carthagenensis*) to be  $43.13 \pm 3.29 \text{ mg GAE/g}$  and  $24.13 \pm 2.94 \text{ mg QE/g}$ , respectively. A significantly higher phenolic content was found in the ethanol-water extract of *C. calophylla* Cham. & Schltdl. (180.51 ± 4.09 mg GAE/g) [52].

The effect of various extraction parameters (e.g., temperature, extraction duration, solvent concentration) on TPC levels in *C. carthagenensis* extracts was further investigated by Bergmeier et al. [27]. For ethanol extraction, different conditions resulted in a wide range of TPC values, from 7.64 to 42.16 mg GAE/g. The highest level of phenolics was recovered when extraction was carried out at 56 °C, for 110 min, in a 50:50 water/ethanol ratio. Acetone extraction yielded TPC values ranging from 4.63 to 37.99 mg GAE/g, with the highest content determined when the extraction was carried out at 40 °C, 110 min, and with a 50:50 water/solvent ratio.

The results of several studies have shown that the phenolic content in individual species tends to be organ specific. Cardenas-Sandoval et al. [53] determined TPC values in different organs of three plants of the genus Cuphea, including C. aequipetala Cav., C. aequipetala var. hispida Koehne, and C. lanceolata W.T. Aiton. The highest phenolic levels were found in the leaves of C. aequipetala and C. aequipetala var. hispida ( $55.62 \pm 0.50$  and  $60.74 \pm 0.23$  mg GAE/g DW, respectively) and in the flowers of C. lanceolata ( $62.79 \pm 0.05$ mg GAE/g DW). In these three *Cuphea* species, the phenolic content was significantly lower in the underground parts compared to the aerial parts, while the stems in all cases were almost devoid of these compounds. Similarly, in *C. aequipetala* and *C. aequipetala* var. hispida, flavonoids were most abundant in the leaves (196.83 ± 2.94 and 124.74 ± 1.28 mg QE/g DW, respectively), while in C. lanceolata (135.81  $\pm$  1.55 mg QE/g DW) in the flowers. In a study by Ismail et al. [54], similar organ-dependent differences in phenolic compound levels were observed for C. ignea A.DC. The ethanolic extract from leaves accumulated a higher phenolic content (212.98  $\pm$  0.13  $\mu$ g GAE/mg) than that obtained from flowers  $(188.25 \pm 0.12 \ \mu g \ GAE/mg)$ . In addition, both alcoholic and aqueous leaf extracts showed a higher flavonoid content (65.932  $\pm$  0.084 µg/mg and 32.372  $\pm$  0.44 µg/mg, respectively) calculated as QE, than the flower extracts. Phenolic content may also depend on cultivation conditions, as shown for greenhouse-grown and wild C. carthagenensis: wild-grown samples contained three times more phenolic compounds (30.81 mg GAE/g DW) than greenhouse-grown plants (9.66 mg GAE/g DW) [16].

In wild *C. carthagenensis* plants, the highest levels of phenolics were observed in the leaves (55.62 mg GAE/g DW), and the lowest in the stems (9.60 mg GAE/g DW), generally confirming the aforementioned organ specificity of the phenolic profiles of *Cuphea* plants. A similar trend was also observed for flavonoid content, which ranged from 53.38 g QE/g DW (stems) to 196.83 g QE/g DW (leaves) in wild-grown *Cuphea*, while it averaged 21.59 g QE/g DW in greenhouse-grown plants.

# 3.3. Other Phytochemicals

Other phytochemicals reported in various *Cuphea* species include triterpenes (e.g., carthagenol; Figure 5), sterols (Figure 6), alkaloids and coumarins (e.g., 5,7-dihydroxy-3-methoxycoumarin 5-O- $\beta$ -glucopyranoside; Figure 7) [55–58].

Table 2 summarizes the results of phytochemical research on the genus Cuphea.




Figure 5. Chemical structures of triterpenes of the genus *Cuphea*.







Figure 6. Chemical structures of sterols of the genus *Cuphea*.





5,7-Dihydroxy-3-methoxycoumarin 5-*O*-β-glucoside Brevifolincarboxylic acid



Cuphea Species	Compound	Reference	Cuphea Species	Compound	Reference
C. acinos A.StHil.			C. appendiculata Benth.		
a) leaves	Apigenin-C-glycoside	[49]	a) aerial part	β-Amyrin	[56]
	Isorhamnetin-3-O-galactoside			Betulinic acid	
				Epifriedelanol	
				β-Sitosterol	
				Stigmasterol	
				Mannitol	
			C. calophylla Cham. & Schltdl.		
C. adenophylla T.B.Cavalc.			a) leaves	Quercetin	[59]
a) leaves	Quercetin-3-O-arabinoside	[49]		Quercetin-3-(2-galloylglucoside)	
,	Quercetin-3-O-glucoside			Quercetin-3-O-(6"-O- $\alpha$ -L-rhamnose)- $\beta$ -D-glucoside	
	Quercetin-3-O-rhamnosylglucoside			Quercetin-3-arabinoside	
	Quercetin-3-O-galactosylgalactosid			Quercetin-3- $O$ - $\alpha$ -L-rhamnoside	
	0 90			Quercetin-3-O-β-glucoside	
C. aequipetala Cav.				Kaempferol	
a) aerial parts	Mannitol	[60]		Kaempferol-3-glucoside	
b) leaves	Quercetin-3-β-D-glucoside	[53]		Kaempferol-galloyl-glucoside	
b) leaves	Quercenn-5-p-D-grucoside	[55]		Kaempferol-3-xyloside	
C. aequipetala var. hispida				Kaempferol-7-rhamnoside	
Koehne				Myricetin-3-(2-galloyl-glucoside)	
a) leaves	Quercetin-3-β-D-glucoside	[53]		Myricetin-3-glucoside	
u) icuves	Sitotenone	[00]		Myricetin-3-xyloside	
	Stigmastenone			Myricetin-3- $O$ - $\alpha$ -L-rhamnoside	
C. aperta Koehne	Cugnasterione		C. calophylla subsp. mesostemon		
a) whole plant	Quercetin	[61]	(Koehne) Lourteig		
	Kaempferol	[*-]	a) fresh aerial parts	Kaempferol	[62]
	Gallic acid		, i i i i i	Gallic acid	[-]
	Methyl gallate			O-Galloylquinic acid	
	Protocatechuic acid			Di-O-galloylquinic acid	
	$\alpha$ -Amyrin, $\beta$ -Amyrin			Brevifolincarboxylic acid	
	Lupeol			Epigallocatechin	
	Stigmasterol			Ellagic acid	
	β-Sitosterol			3-O-Methyl ellagic acid 4'-sulfate	
	Campestenone, Sitostenone, Stigmastenone			3-O-Methyl ellagic acid	

# **Table 2.** Compounds reported in the genus *Cuphea*.

C. carthagenensis (Jacq.)			C. crulsiana Koehne		
J.F.Macbr.			a) leaves	Quercetin	[49]
a) aerial parts	β-Sitosterol, Stigmasterol	[56]		Quercetin-3-O-arabinoside	
	Epifriedelanol			Quercetin-3-O-(glucose-rhamnose)	
	Ergosterol, Carthagenol			Rhamnetin-3-O-glucoside	
	β-Amyrin			Isorhamnetin-3-O-arabinoside	
	Lauric acid, Myristic acid		C. diosmifolia A.StHil.		
	Betulinic acid, Ursolic acid		a) leaves	Quercetin	[49]
	Mannitol			Quercetin-3-O-galactoside	
	Quercetin-3-sulfate			Quercetin-3-O-(glucose-glucuronic acid)	
	Quercetin-5-O-β -glucoside			Rhamnetin-3-O-galactoside	
	Quercetin-3-O-β-arabinofuranoside			Myricetin-3-O-galactoside	
	Quercetin-3-sulfate			Myricetin-3-O-glucoside	
b) fresh aerial parts	Quercetin	[50]		-	
c) aerial parts	Quercetin-5-O-β-glucoside	[45]			
	Quercetin-3-O-(6"-O-α-L-rhamnosyl)-β-D-	[-0]			
	glucoside		C. disperma A.StHil.		
d) leaves	Quercetin-3-O-β-D-glucuronide	[60,62]	a) leaves	Apigenin-C-glycoside	[49]
	Quercetin-3-O-β-glucoside			Quercetin-3-O-arabinoside	
	Quercetin-3-sulfate			Quercetin-3-O-galactoside	
	Quecertin-3-O-arabinofuranoside			Quercetin-3-O-glucosyl-glucosyl-glucoside	
	Kaempferol				
	Kaempferol-rutinoside				
	Kaempferol-3-glucoside		C. epilobiifolia Koehne		
	Kaempferol 3,7-dirhamnoside		a) aerial part	β-Sitosterol, β-Amyrin	[56]
	Myricetin-glucoside		a) actual part	Epifriedelanol	[50]
	Chlorogenic acid			Betulinic acid	
				Mannitol	
			C. ericoides Cham. & Schltdl.		
			a) leaves	Quercetin-3-O-galactoside	[49]
				Kaempferol-3-O-galactoside	
				Myricetin-3-O-arabinosyl-arabinoside	
C. cipoensis T.B.Cavalc.		[40]		Myricetin-3-O-galactosyl-galactosyl-galactoside	
a) leaves	Isorhamnetin-3-O-galactoside Myricetin-3-O-galactoside	[49]			

C. glutinosa Cham. & Schltdl			C. hyssopifolia		
a) whole plant	Quercetin Quercetin-3-Ο-β-glucoside Kaempferol β-Sitosterol-3-Ο-β-glucoside Methyl gallate Gallic acid	[63]	a) aerial part (cont.)	Methyl gallate Epifriedelanol Ursolic acid Mannitol 1,3-O-Digalloyl-4-,6-hexahydroxydiphenoyl-β-D-4C1-glucoside Genistein-7-O-β-D-4C1-glucoside	
b) leaves	Quercetin Quercetin-3- $O$ - $\beta$ -D-glucuronide Quercetin-3-arabinoside Quercetin-3- $O$ - $\alpha$ -L-rhamnoside Quercetin-acetyl-glucuronide Quercetin-3- $O$ - $\beta$ -glucoside Kaempferol Kaempferol-3-glucoside Kaempferol-3-glucuronide	[45,60]		Myricetin-3- <i>O</i> -β-D- <i>4</i> C <i>i</i> -glucoside Valoneic acid dilactone Gallic acid 3,4,5-Trimethoxy benzoic acid Vanillic acid	
	6"-O-Galloylquercimeritrin Isorhamnetin Myricetin-3-O-glucuronide 3-Feruloylquinic acid		<i>C. ignea</i> A.DC. a) fresh plant b) leaves	7-Hydroxy-3-methoxycoumarin 5- <i>O</i> -β-glucoside Quercetin Quercetin-3- <i>O</i> -(6"- <i>O</i> -α-L-rhamnose)-β-D-glucoside Naringenin Myricetin-3- <i>O</i> -rhamnoside Catechin	[57] [64]
<i>C. hyssopifolia</i> Kunth				<i>p-</i> Coumaric acid <i>o-</i> Coumaric acid Gallic acid Caffeic acid Syringic acid	
a) aerial part	1,2,3,6-Tetra-O-galloyl-β-D-glucose 1,2,3,4,6-Penta-O-galloyl-β-D-glucose Myricetin 3- $O$ - $\alpha$ -L-rhamnoside Tellimagrandin II Woodfordin C Oenothein B Cuphiin D <sub>1</sub> Cuphiin D <sub>2</sub> Quercetin Quercetin-3- $O$ - $\alpha$ -rhamnoside	[47,64,65]		Vanillic acid Cinnamic acid Rosmaric acid Chlorogenic acid Resveratrol	

C. ingrata Cham. & Schltdl.			C. linarioides Cham. & Schltdl.		
a) leaves and thalli	Caffeine	[65]	a) leaves	Myricetin-3-O-glucoside	[49]
b) aerial parts	Quercetin	[47]		Myricetin-3-O-rhamnoside	
	Quercetin-3-O-(6"-O-α-L-rhamnose)-β-D-gluco-			Myricetin-3-O-(glucose-rhamnose)	
	side				
	Quercetin-3-O-β-D-glucoside		C. lindmaniana Koehne ex Bacig.		
	Quercetin-3-O-β-D-glucuronide		a) leaves	Ouercetin	[66]
	Quercetin-3- $O$ - $\alpha$ -L-arabinoside		a) leaves	Quercetin 3- <i>O</i> -β-D-glucuronide	[00]
	Quercetin-3- $O$ - $\alpha$ -L-arabinofuranoside			Ouercetin-3-arabinoside	
	Quercetin sulfate			Quercetin-o-arabinoside Quercetin-acetyl-glucuronide	
	Quercetin-3-O-β-D-glucuronide butyl ester			Quercetin-3-(4"-malonylrhamnoside)	
	Kaempferol			Quercetin-3-O-β-glucoside	
	Kaempferol-3- <i>O</i> -(6"- <i>O</i> -α-L-rhamnose)-β-D-			Kaempferol	
	glucoside			Kaempferol-3-xyloside	
	Kaempferol-3- <i>O</i> -β-D-glucoside			Kaempferol-3-glucuronide	
	Methyl gallate, Gallic acid			3-Methylellagic acid 8-rhamnoside	
	Protocatechuic acid			Chlorogenic acid	
	<i>p</i> -Hydroxybenzoic acid			Chicoric acid	
	Caffeic acid, Syringic acid				
	Vanillic acid, <i>p</i> -Coumaric acid				
	1,3-Dicaffeoylquinic acid		C. lutea Rose ex Koehne		
	Ferulic acid		a) seed oil	Campesterol	[67]
	Ellagic acid		-,	Stigmasterol	[*.]
	1,5-Dicaffeoylquinic acid Oenothein B			β-Sitosterol	
				$\Delta$ 5-Avenasterol	
	Cuphiin D2/Woodfordin C			$\Delta$ 7-Stigmastenol	
			C. lutescens Pohl ex Koehne		
			a) leaves	Quercetin-3-O-galactoside	[49]
C. lanceolata W.T.Aiton			, ,	Quercetin-3-O-glucoside	
a) seed oil	Campesterol	[67]		Quercetin-3-O-(arabinose-glucose)	
•	Stigmasterol			Isorhamnetin-3-O-(glucose-rhamnose)	
	β-Sitosterol			Myricetin-3-O-arabinoside	
	$\Delta$ 5-Avenasterol			Myricetin-3-O-galactoside	
	$\Delta$ 7-Stigmastenol			Myricetin-3-O-(arabinose-galactose)	
b) leaves	Quercetin-3-β-D-glucoside	[53]		, , , , , , , , , , , , , , , , , , ,	

C. paucipetala S.A.Graham			C. racemosa (L.f.) Spreng.		
a) seed oil	Campesterol Stigmasterol β-Sitosterol	[67]	a) leaves	Quercetin Quercetin-3,7-diglucoside Quercetin-3- <i>O</i> -(6''- <i>O</i> -α-L-rhamnose)-β-D-glucoside	[59]
	Δ5-Avenasterol			Quercetin-3-O-β-D-glucuronide	
	$\Delta$ 7-Stigmastenol			Ouercetin-3-arabinoside	
				Quercetin-3- <i>O</i> -β-glucoside	
				Kaempferol	
C. pinetorum Benth.				Kaempferol-3-O-rutinoside	
a) roots	Quercetin	[68]		Kaempferol-3-glucuronide	
a) 100ts	Kaempferol	[00]		Myricetin-3-O-glucuronide	
b) aerial part	Quercetin	[69]		Myricetin-3-O-glucoside	
of action part	Ouercetin-3- $O$ - $\alpha$ -rhamnoside	[02]		Myricetin-3- <i>O</i> -α-L-rhamnoside	
	Kaempferol			Chlorogenic acid, 3-Feruloylquinic acid	
	Luteolin-7-O-β-D-glucoside				
	Apigenin-7- $O$ - $\alpha$ -rhamnoside				
	Apigenin-7- <i>O</i> -β-D-glucoside				
	Squalene, β-Sitosterol				
	1		C. rubrovirens T.B.Cavalc.		
			a) leaves	Quercetin-3-O-galactoside	[49]
				Quercetin-3-O-(galactose-glucose)	
				Rhamnetin-3-O-galactoside	
C. pseudovaccinium A.StHil.			C. sclerophylla Koehne		
a) leaves	Quercetin	[49]	a) leaves	Quercetin	[49]
	Quercetin-3-O-galactoside			Quercetin-3-O-galactoside	
	Quercetin-3-O-(galactose-rhamnose)			Luteolin-7-O-galactoside	
	Kaempferol-3-O-(galactose-glucose)			Luteolin-7-O-(glucose-glucuronic acid)	
	Kaempferol-3-O-(glucose-rhamnose)			Myricetin-3-O-glucoside	
	Myricetin				
			C. sessilifolia Mart.		
			a) leaves	Quercetin-3-O-arabinoside	[49]
C. pulchra Moric.			,	Quercetin-3-O-galactoside	
a) leaves	Quercetin-3-O-arabinoside	[49]		Quercetin-3-O-(galactose-glucose)	
	Quercetin-3-O-galactosyl-galactoside			Quercetin-3-O-(galactose-glucuronic acid)	
	Quercetin-3-O-rhamnosyl-glucoside			Quercetin-3-O-glucosyl-glucoside	
	Rhamnetin-3-O-glucoside			Quercetin-3-O-(glucose-glucuronic acid)	
	Isorhamnetin-3-O-xyloside			Quercetin-3-O-rhamnosyl-glucoside	
	Myricetin			Myricetin-3-O-galactoside	

C. sperguloides A.StHil			C. viscosissima Jacq.		
a) leaves	Myricetin-3-O-galactoside	[49]	a) seed oil	Campesterol	[67]
				Stigmasterol	
C. teleandra Lourteig				β-Sitosterol	
a) leaves	Ouercetin-3-O-arabinoside	[49]		$\Delta 5$ -Avenasterol	
a) leaves	Quercetin-3-O-glucoside	[17]		$\Delta$ 7-Stigmastenol	
	Quercetin-3-O-(glucose-rhamnose)				
	Isorhamnetin-3-O-galactoside				
	0		C. wrightii A.Gray		
C. urbaniana Koehne			a) seed oil	Campesterol	[67]
a) leaves	Quercetin	[66]		Stigmasterol	
	Quercetin-4'-galactoside			β-Sitosterol	
	Quercetin-3-O-(6"-O-α-L-rhamnose)-β-D-gluco-			$\Delta$ 5-Avenasterol	
	side			$\Delta$ 7-Stigmastenol	
	Quercetin-3-O-β-D-glucuronide		b) whole plant	Quercetin-3- <i>O</i> -β-D-galactoside	[70]
	Quercetin-3-O-malonylglucoside			Luteolin-7- $O$ - $\beta$ -D-glucoside	
	Quercetin-galloyl rhamnoside			β-Sitosterol-3-O-β-D-glucoside	
	Quercetin-3- $O$ - $\alpha$ -L-rhamnoside			Epifriedelanol	
	Quercetin-3- <i>O</i> -β-glucoside			Fernenol	
	Kaempferol			Germanicol Ursolic acid	
	Kaempferol-3-glucoside			Mannitol	
	Apigenin-7-O-glucoside			mannutor	

# 4. Cuphea Plants in Traditional Medicine

Plants belonging to the genus *Cuphea* are important components of the traditional *materia medica* of the regions where they grow in the wild. For example, some *Cuphea* species are used in traditional South American medicine as contraceptives. This has been recorded for the Kayapo Indians of Brazil's Amazon Basin [71]. In Argentina, *C. glutinosa*, *C. longiflora*, and *C. racemosa* are used as emmenagogues, and the latter also as an abortifacient.

Recently, an extract of *C. aequipetala* has been suggested as a potential antibacterial agent to be considered for the treatment of *E. coli* and *Staphylococcus* sp. infections in equine hospitals, particularly to avoid cross-transmission in horses and to reduce the risk of infections in equine workers [72]. The use of aerial parts of *C. carthagenensis* in animal self-medication has also been observed; for example, dogs have consumed the herb to relieve symptoms of diarrhea [73].

Traditional uses, forms of preparation, and routes of administration of *Cuphea* plants are presented in Table 3.

Species	Part of the Plant	Form (Route of Admin- istration)	Traditional Use	Reference
C. aequipetala	aerial parts	decoction (topically; wound washing)	wound healing bumps bruises throat pain	[18]
		infusion	cough gastrointestinal disorders	
		not mentioned	diarrhea stomachache	[74]
C. calophylla var. macrostemon	aerial parts	decoction	anti-hypertensive	[75]
	leaves, aerial parts	decoction (orally)	anti-hypertensive lipid-lowering	[76]
	whole plant leaves roots	maceration infusion	not mentioned	[77]
	roots	decoction (orally)	anti-hypertensive	[78]
	aerial parts	infusion (orally)	intestinal and heart prob- lems	[79]
C. carthagenensis	stems and leaves	maceration in rum (topically)	sprains	[80]
	stems and leaves	infusion (orally)	colds, chills	[00]
	not mentioned not mentio		digestive problems diarrhea stomachache bowel infections leg pain varicose veins	[81]
C. epilobiifolia	stems	decoction (orally)	rheumatism	[82]

Table 3. Medicinal uses of Cuphea plants.

	leaves	decoction (baths)	rheumatism	
C. glutinosa	aerial parts	infusion (orally)	hypercholesteremia	[83]
			cough	
C. hyssopifolia	leaves and flowers		fever	[84]
C. ingrata	whole plant leaves stems	maceration infusion	as insecticide and tonic cardiovascular system dis- eases musculoskeletal and joint diseases	[85]
C. lysimachioides	xylopodium	infusion	diarrhea as astringent	[86]
C. pinetorum	aerial parts	decoction decoction (orally) infusion	throatache diarrhea dysentery	[69]
C. racemosa	not mentioned	decoction (orally)	anti-hypertensive	[87]
C. urticulosa	leaves	ground up leaves (topically)	rashes lice	[88]

The use of *C. carthagenensis* in traditional rituals has also been reported. In the Brazilian Kiki ritual performed for the Kaingang dead, graves are marked with pine and *Cuphea* branches [89,90]. Other examples of non-medical uses include the use of *C. aequipetala* herb to obtain pigment for painting [18].

# 5. Pharmacological Activity of Cuphea Plants and Phytochemicals

The pharmacological activity of plants of the genus *Cuphea* is multidirectional (Figure 8). Research was primarily inspired by the directions of traditional medicinal use, and focused on the evaluation of activity and mechanisms of action. The composition of the extracts and the presence of a number of bioactive phytochemicals justified the observed pharmacological activity. It should be emphasized that pharmacological studies confirmed most of the traditional uses of these plants. The results of pharmacological studies conducted on extracts and on partially purified fractions are presented in Table 4.




Figure 8. Biological activity of *Cuphea* extracts.

Table 4. The results of	pharmacological	studies on	<i>Cuphea</i> sp.
-------------------------	-----------------	------------	-------------------

Cuphea Species	<b>Biological Activ</b>	- Results	Assay/Model	Refer-
	ity Tested			ences
C. aequipetala	antinociceptive	- antinociception in the acetic acid	male Balb/c mice	[91]
(ethanol extract from	n	test (dose-dependent $\downarrow$ in the num	n-in vivo acetic acid-induced writhing	
leaves and stems)		ber of abdominal constrictions,	test	
		$ED_{50}=90$ mg/kg) and in the second	d in vivo formalin test	
		phase of the formalin test ( $ED_{50}$ =	in vivo hot plate test	
		158 mg/kg), probably due to the		
		involvement of nitric oxide and		
		ATP-sensitive K <sup>+</sup> channels		
	anti-inflamma-	- no effect in hot-plate test (doses:		
	tory	50–200 mg/kg)	in vitro LPS-stimulated primary mu-	
			rine macrophages	
		- inhib. of production of NO (IC50	=	
		420 $\mu$ M/mL) and H <sub>2</sub> O <sub>2</sub> (IC <sub>50</sub> =416		
		µM/mL) in LPS-treated macro-		
		phages in a concentration-depend	-	
		ent manner		
		- significant ↑ in the production of		
		IL-10 (EC <sub>50</sub> = 10 pg/mL)	in vivo TPA-induced ear oedema	
		-↓ of ear oedema by 25.7% after	male Balb/c mice	
		topical application of 2 mg of the	in vivo carrageenan-induced mouse	
		extract	paw oedema	
		- $\downarrow$ of the levels of IL-1 $\beta$ , IL-6, TNF	7_	
		$\alpha$ , and PGE2 induced by the ex-		
		tract at the concentration of 100		
		mg/kg and 200 mg/kg		

<i>C. aequipetala</i> (ethanol extract from shoots and leaves)	anti-lipase	<ul> <li>non-competitive inhib. of porcine pancreatic lipase (PPL) up to 60%</li> <li>effect on the kinetic parameters of PPL: Km (mM) 0.365 ± 0.014 at</li> </ul>	e in vitro inhib. of PPL	[92]
		the concentration of 50 $\mu$ g/mL 0.362 ± 0.019 at the concentration of 100 $\mu$ g/mL		
	antioxidant	- high antioxidant activity against the DPPH radical with IC50=6.5 μg/mL	in vitro DPPH assay	
C. aequipetala (methanol extracts from leaves, stems and roots of wild- grown and green- house grown plants)	antioxidant	<ul> <li>free-radical scavenging activity of extracts [μM trolox/g DW]</li> <li>from wild-grown plants: leaves 169.33 ± 2.10 stems 19.19 ± 0.10 roots 85.62 ± 0.48</li> </ul>	- in vitro DPPH assay	[16]
		leaves 494.37 ± 8.6 stems 106.71 ± 0.3 roots 209.38 ± 1.2	- in vitro ABTS assay	
		- from greenhouse grown plants: leaves $87.83 \pm 0.8$ stems $21.86 \pm 0.3$ roots $43.26 \pm 0.2$	- in vitro DPPH assay	
		leaves 119.50 ± 0.3 stems 117.74 ± 0.2 roots 43.38 ± 0.1	- in vitro ABTS assay	
<i>C. aequipetala</i> (extracts from leaves) flowers and stems)	antimicrobial	- no significant inhib. of bacteria and yeast cultures growth com- pared to common antibiotics: amoxicillin, ampicillin, carbenicil- lin, cephalotaxin, cephalothin, chloramphenicol, fosfomycin, gen tamicin, penicillin, sulfamethoxa- zole, trimethopim	in vitro disc-diffusion method Staphyllococcus aureus, Staphyllococcus sp. coagulase-negative, Enterococcus faecalis, Escherichia coli, Candida albi- cans	[93]
<i>C. aequipetala</i> (methanol and aque- ous extracts from aerial parts)	anti-Helicobacter pylori	<ul> <li>- inhib. of the growth of <i>H. pylori</i></li> <li>- aqueous extract: MIC 125 μg/mL</li> <li>- methanol extract: MIC &gt;500 μg/mL</li> </ul>	0	[74]
<i>C. aequipetala</i> (aqueous extracts from aerial parts prepared by infu- sion)	anti-Helicobacter pylori	<ul> <li>- inhib. of the growth of <i>H. pylori</i></li> <li>in a concentration dependent manner</li> <li>- promotion of bacterial lysis</li> <li>- MIC 125 μg/mL</li> </ul>		[94]
	gastroprotective	<ul> <li>↓ of the ethanol-induced gastric lesions in a dose-dependent manner</li> <li>88% protective effect of the extract at the dose of 300 mg/kg, comparable to the effect (87%) of the reference drug carbenoxolone</li> </ul>	male CD-1 mice in vivo ethanol-induced gastric ulcer model	
	anti-inflamma- tory	at the dose of 100 mg/kg	male CD-1 mice in vivo xylene and TPA-induced ear edema	

	- xylene-induced ear edema inhib.	
	[%] after topical application of the	2
	extract	
	$2.4 \pm 2.7$ at the dose of 0.1 mg of	
	the extract	
	14.6 ± 2.5 at the dose of 0.25 mg	
	$22.0 \pm 4.0$ at the dose of 0.5 mg	
	- xylene-induced ear edema inhib.	
	[%] after oral application of the ex	(-
	tract	
	$16.9 \pm 4.4$ at the dose of 10 mg/kg	
	of the extract	
	$36.4 \pm 7.7$ at the dose of 30 mg/kg	
	$35.0 \pm 3.0$ at the dose of 100 mg/kg	
	- TPA-induced ear edema inhib.	
	[%] after topical application of the	2
	extract	
	$10.4 \pm 2.0$ at the dose of 0.1 mg of	
	the extract	
	$14.3 \pm 3.0$ at the dose of 0.25 mg	
	$23.7 \pm 4.9$ at the dose of 0.5 mg	
	- TPA-induced ear edema inhib.	
	[%] after oral application of the ex	(-
	tract	
	$12.2 \pm 1.4$ at the dose of 10 mg/kg	
	of the extract	
	$15.6 \pm 2.2$ at the dose of 30 mg/kg	
	$27.3 \pm 1.0$ at the dose of 100 mg/kg	
C. aequipetala var. his-antimicrobial		- in vitro agar diffusion susceptibility [72]
pida	aration of 50% ethanolic extracts	test disc method
(aqueous-ethanol	carried out with a	Listeria monocytogenes (ATCC 19115),
extract)		n-Staphylococcus sp., Escherichia coli
	centration)	(ATCC 25922), Salmonella enterica
	L. monocytogenes $7.0 \pm 0.0$	serotype Enteritidis (ATCC 13076)
	Staphylococcus sp. $10 \pm 1.0$	
	E. coli $8 \pm 0.03$	in vitro ABTS assay
antioxidant	S. enterica $8.0 \pm 1.0$	
	- free-radical scavenging activity	
	[uM TEAC/g]—1756.59 ± 1.9	
C balsamona Cham. & hypocholestere-		young adult male Wistar rats submit- [95]
Schltdl. mic	triglycerides blood levels (vs. con-	-
(aqueous extract)	trol) during chronic treatment	in vivo dyslipidemia model
	with different concentrations of	
	aqueous extract	
	- 50 mg/L	
	total cholesterol $500.0 \pm 108.25$ (vs	
	857.81 ± 56.22)	
	triglycerides 80.95 ± 27 (vs. 173.80	
	± 63.35)	
	HDL 38.65 ± 1.,03 (vs. 69.32 ± 3.34)	)
	VLDL 16.31 ± 5.36 (vs. 34.75 ±	
	12.67)	
	LDL 445.16 ± 101.71 (vs. 753.73 ±	
	55.17)	
	- 100 mg/L	
	total cholesterol 684.37 ± 98.22	
	(vs. 857.81 ± 56.22)	

		triglycerides $61.90 \pm 22.67$ (vs. 173.80 $\pm 63.35$ ) HDL 48.28 $\pm 7.33$ (vs. $69.32 \pm 3.34$ ) VLDL 12.37 $\pm 4.53$ (vs. 34.75 $\pm$ 12.67)	Y	
<i>C. calophylla</i> (aqueous–ethanol extract of aerial parts)	antioxidant	LDL $623.72 \pm 92$ (vs. $753.73 \pm 55.17$ - free-radical scavenging activity [ $\mu$ M ET/g] - 1761.92 $\pm$ 3.05 - 3756.65 $\pm$ 2.48	) in vitro FRAP assay in vitro ORAC assay	[52]
<i>C. calophylla</i> (aqueous–ethanol extract of leaves)	anti-inflamma- tory	<ul> <li>significant ↓ in the ROS levels</li> <li>no significant cytoprotective effect on the cell death induced by LPS and no effect on NO production in macrophages</li> <li>inhib. activity against COX and LOX</li> <li>100% inhib. of PMNs migration at the concentration 10 µg/mL</li> </ul>	in vitro inhib. of rat PMNs chemo- taxis, employing a modified Boyden chamber	[96]
<i>C. carthagenensis</i> (ethanol–aqueous extract of leaves)	antihypertensive	- ACE-inhib. activity: 26,12% at the concentration of 100 ng/mL	in vitro ACE-inhib. assay	[59]
<i>C. carthagenensis</i> (dichloromethane– methanol extract of leaves)	antihypertensive	- ACE-inhib. activity: 50% at the concentration of 100 μg/mL	in vitro ACE-inhib. assay	[79]
<i>C. carthagenensis</i> (infusion of aerial	diuretic	- no changes in renal function or cortical blood flow	male Wistar rats in vivo laser-Doppler flowmetry	[97]
parts and ethanol- soluble fraction)	antioxidant	<ul> <li>DPPH free radical scavenging of ethanol-soluble fraction:</li> <li>IC<sub>50</sub>=18 ± 4.1 ug/mL</li> <li>max activity -95 ± 1.8% at the concentration of 30 ug/mL</li> </ul>	in vitro DPPH assay	
		<ul> <li>NO radical scavenging of ethanol-soluble</li> <li>fraction:</li> <li>IC<sub>50</sub>=465 ± 4.1 ug/mL</li> <li>max activity -68 ± 2.5% at the concentration of 1000 ug/mL</li> </ul>	in vitro nitric oxide radical assay	
<i>C. carthagenensis</i> (aqueous extract of aerial parts and iso- lated fractions)	antinociceptive	-↓ of the acetic acid-induced writhing in mice by aqueous ex- tract (10 to 100 mg/kg) and semi- purified fraction (0.1 to 10 mg/kg) by 40 to 50% and by 46 to 70% of control, respectively; no effect in	adult albino male mice in vivo acetic acid-induced writhing test in vivo tail flick test	[98]
	anti-inflamma- tory	the tail flick response - the carrageenin-induced paw edema volume ↓ by semi-purified fraction at a dose of 100 mg/kg (p.o.) by 82% in the 1st hour after carrageenin injection and by 37% in the 3rd hour	in vivo carrageenan-induced rat paw oedema	
C. carthagenensis	serum lipid-low- ering	- $\downarrow$ in oxidative stress and significant $\downarrow$ of the CAT (17,274.7 $\mu$ M min mg) and $\uparrow$ of the SOD (3571.2	New Zealand (NZ) rabbits undergo- ing cholesterol-rich diet	[99]

	-
of leaves) of leaves) nol-soluble fraction (100 mg/kg) - no significant change in the glu- tathinone-Stransferse activity - 1 of the serum triglycerides (TG), total cholesterol fractions (LDL-C and VLDL-C) levels and 1 of the level of HDL-C after 4-weeks- treatment (vs. possitive control) - at dose of 10 mg/kg TG 166 ± 35 (vs. 185 ± 20) VLDL-C 78 ± 92 (vs. 81 ± 10) HDL-C 82 ± 0.2 (vs. 72 ± 0.3) - at dose of 30 mg/kg TG 140 ± 31 (vs. 190 ± 28) LDL-C 122 ± 15 (vs. 185 ± 20) VLDL-C 57 ± 69 (vs. 81 ± 10) HDL-C 8.2 ± 0.2 (vs. 72 ± 0.3) - at dose of 100 mg/kg TG 147 ± 25 (vs. 190 ± 28) LDL-C 122 ± 15 (vs. 185 ± 20) VLDL-C 56 ± 7.1 (vs. 81 ± 10) HDL-C 8.6 ± 0.4 (vs. 72 ± 0.3) - no significant 4 (vs. 72 ± 0.3) - cholesterol (mg/dL] 57 ± 9 (vs. 96 ± 23) - no significant effect on glycemic level, body weight and triglyceride level in comparison to control group C. carthagenensis (thanol and aque- ous extracts of aerial parts and derived fractions) vasorelaxant (thanol and aque- ous extracts of aerial parts and derived fractions) HDL-C 82 ± 1.0] - notaginificant effect on glycemic level, body weight and triglyceride level in comparison to control group - vasodilatation mpre-contracted ext vivo aortic rings with functional at end with polyphenolic com- pounds - vasodilatation mole. - vasodilatation mole. - vasodilatation field (af6.8 ± 14.4) - <i>n</i> -butanol fraction 4.98 ± 0.06 (86.2 ± 1.6) - methanol-insoluble water frac-	
<ul> <li>- no significant change in the glutathione-S-transferase activity</li> <li>-   of the serum triglycerides (TG), total cholesterol fractions (LDL-C and VLDL-C) levels and 1 of the level of HDL-C after 4-weeks- treatment (vs. positive control)</li> <li>- at dose of 10 mg/kg</li> <li>TG 166 ± 35 (vs. 190 ± 28)</li> <li>LDL-C 78 ± 92 (vs. 81 ± 10)</li> <li>HDL-C 78 ± 92 (vs. 81 ± 10)</li> <li>HDL-C 78 ± 0.8 (vs. 7.2 ± 0.3)</li> <li>- at dose of 100 mg/kg</li> <li>TG 140 ± 31 (vs. 190 ± 28)</li> <li>LDL-C 112 ± 15 (vs. 185 ± 20)</li> <li>VLDL-C 52 ± 0.2 (vs. 7.2 ± 0.3)</li> <li>- at dose of 100 mg/kg</li> <li>TG 147 ± 25 (vs. 190 ± 28)</li> <li>LDL-C 122 ± 15 (vs. 185 ± 20)</li> <li>VLDL-C 52 ± 0.2 (vs. 7.2 ± 0.3)</li> <li>- at dose of 100 mg/kg</li> <li>TG 147 ± 25 (vs. 190 ± 28)</li> <li>LDL-C 112 ± 17 (vs. 185 ± 20)</li> <li>VLDL-C 56 ± 0.4 (vs. 7.2 ± 0.3)</li> <li>- at dose of 100 mg/kg</li> <li>TG 147 ± 25 (vs. 190 ± 28)</li> <li>LDL-C 112 ± 17 (vs. 185 ± 20)</li> <li>VLDL-C 56 ± 0.4 (vs. 7.2 ± 0.3)</li> <li>- at dose of 100 mg/kg</li> <li>TG 147 ± 25 (vs. 190 ± 28)</li> <li>LDL-C 112 ± 17 (vs. 185 ± 20)</li> <li>VLDL-C 56 ± 0.4 (vs. 7.2 ± 0.3)</li> <li>- avoillatation on pre-contracted</li> <li>evelve, how weight com significant [in cholesterolemia male Wistar rats undergoing a high while chronic (4-weeks; infusion calorie diet administrated to the rats ad libitum) treatment (vs. control)</li> <li>- cholesterol [mg/dL] 57± 9 (vs. 96 ± 23)</li> <li>- no significant effect on glycemic level, hody weight and triglyceride level in comparison to control group</li> <li>- cavodilatation on pre-contracted</li> <li>endothelium, pre-contracted with at at divite rigber probably associated with polyphenolic comparises is a derived in the polyphenolic comparises</li> <li>- vasodilatation fpCs] (max vaso-dilatation %):</li> <li>- ethanol extract 4.92 ± 0.11 (81.8 ± 5.1)</li></ul>	
$ \begin{array}{c} tathione-S-transferase activity \\ -1 of the serum trighycerides (TG), \\ total cholesterol fractions (DL-C \\ and VLDL-C) levels and 1 of the \\ level of HDL-C after 4-weeks. \\ treatment (vs. positive control) \\ -at dose of 10 mg/kg \\ TG 166 \pm 35 (vs. 185 \pm 20) \\ VLDL-C 78 \pm 92 (vs. 81 \pm 10) \\ HDL-C 7.8 \pm 92 (vs. 81 \pm 10) \\ HDL-C 78 \pm 0.8 (vs. 7.2 \pm 0.3) \\ -at dose of 30 mg/kg \\ TG 140 \pm 31 (vs. 190 \pm 28) \\ LDL-C 122 \pm 15 (vs. 185 \pm 20) \\ VLDL-C 57 \pm 69 (vs. 81 \pm 10) \\ HDL-C 82 \pm 0.2 (vs. 7.2 \pm 0.3) \\ -at dose of 100 mg/kg \\ TG 147 \pm 25 (vs. 185 \pm 20) \\ VLDL-C 57 \pm 69 (vs. 81 \pm 10) \\ HDL-C 84 \pm 0.4 (vs. 7.2 \pm 0.3) \\ -at dose of 100 mg/kg \\ TG 147 \pm 25 (vs. 190 \pm 28) \\ LDL-C 122 \pm 15 (vs. 185 \pm 20) \\ VLDL-C 56 \pm 7.1 (vs. 81 \pm 10) \\ HDL-C 86 \pm 0.4 (vs. 7.2 \pm 0.3) \\ \end{array} $	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	
$ \begin{array}{c ccc} total cholesterol fractions (LDL-C and VLDL-C) levels and \uparrow of the level of HDL-C after 4-weeks-treatment (vs. positive control) - at dose of 10 mg/kg TG 166 ± 33 (vs. 190 ± 28) LDL-C 166 ± 33 (vs. 190 ± 28) LDL-C 166 ± 33 (vs. 190 ± 28) LDL-C 78 ± 9.2 (vs. 81 ± 10) HDL-C 78 ± 9.0 (vs. 81 ± 10) HDL-C 78 ± 9.0 (vs. 72 ± 0.3) - at dose of 30 mg/kg TG 140 ± 31 (vs. 190 ± 28) LDL-C 122 ± 15 (vs. 185 ± 20) VLDL-C 57 ± 6.9 (vs. 81 ± 10) HDL-C 8.2 ± 0.2 (vs. 7.2 ± 0.3) - at dose of 10 mg/kg TG 147 ± 25 (vs. 190 ± 28) LDL-C 117 ± 17 (vs. 185 ± 20) VLDL-C 55 ± 6.9 (vs. 81 ± 10) HDL-C 8.6 \pm 0.4 (vs. 7.2 \pm 0.3) \\ \hline \\ $	
$\begin{tabular}{l l l l l l l l l l l l l l l l l l l $	
$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	
$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	
$ \begin{array}{c} \text{LDL-C } 166 \pm 33 \ (\text{vs.} 185 \pm 20) \\ \text{VLDL-C } 78 \pm 9.2 \ (\text{vs.} 81 \pm 10) \\ \text{HDL-C } 78 \pm 9.2 \ (\text{vs.} 81 \pm 10) \\ \text{HDL-C } 78 \pm 0.8 \ (\text{vs.} 7.2 \pm 0.3) \\ - at dose of 30 \ mg/kg \\ \text{TG } 140 \pm 31 \ (\text{vs.} 190 \pm 28) \\ \text{LDL-C } 122 \pm 15 \ (\text{vs.} 81 \pm 10) \\ \text{HDL-C } 8.2 \pm 0.2 \ (\text{vs.} 7.2 \pm 0.3) \\ - at dose of 100 \ mg/kg \\ \text{TG } 147 \pm 25 \ (\text{vs.} 190 \pm 28) \\ \text{LDL-C } 17 \pm 17 \ (\text{vs.} 185 \pm 20) \\ \text{VLDL-C } 56 \pm 7.1 \ (\text{vs.} 81 \pm 10) \\ \text{HDL-C } 8.6 \pm 0.4 \ (\text{vs.} 7.2 \pm 0.3) \\ - at dose of 100 \ mg/kg \\ \text{TG } 147 \pm 25 \ (\text{vs.} 190 \pm 28) \\ \text{LDL-C } 17 \pm 17 \ (\text{vs.} 185 \pm 20) \\ \text{VLDL-C } 56 \pm 7.1 \ (\text{vs.} 81 \pm 10) \\ \text{HDL-C } 8.6 \pm 0.4 \ (\text{vs.} 7.2 \pm 0.3) \\ \end{array} $	
$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	
$\begin{array}{c} \text{HDL-C}7.8\pm0.8~(\text{vs}.7.2\pm0.3)\\ -\text{at dose of 30~mg/kg}\\ \text{TG 140\pm31~(\text{vs}.190\pm28)}\\ \text{LDL-C 122\pm15~(\text{vs}.185\pm20)}\\ \text{VLDL-C}57\pm6.9~(\text{vs}.81\pm10)\\ \text{HDL-C}8.2\pm0.2~(\text{vs}.7.2\pm0.3)\\ -\text{at dose of 100~mg/kg}\\ \text{TG 147\pm25~(\text{vs}.190\pm28)}\\ \text{LDL-C 117\pm17~(\text{vs}.185\pm20)}\\ \text{VLDL-C 56\pm7.1~(\text{vs}.81\pm10)}\\ \text{HDL-C}8.6\pm0.4~(\text{vs}.7.2\pm0.3)\\ \end{array}$	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
$ \begin{array}{c} {\rm TG} \ 140 \pm 31 \ ({\rm vs.} \ 190 \pm 28) \\ {\rm LDL-C} \ 122 \pm 15 \ ({\rm vs.} \ 185 \pm 20) \\ {\rm VLDL-C} \ 57 \pm 6.9 \ ({\rm vs.} \ 81 \pm 10) \\ {\rm HDL-C} \ 8.2 \pm 0.2 \ ({\rm vs.} \ 7.2 \pm 0.3) \\ {\rm - at \ dose \ of \ 100 \ mg/kg } \\ {\rm TG} \ 147 \pm 25 \ ({\rm vs.} \ 190 \pm 28) \\ {\rm LDL-C} \ 117 \pm 17 \ ({\rm vs.} \ 185 \pm 20) \\ {\rm VLDL-C} \ 56 \pm 7.1 \ ({\rm vs.} \ 81 \pm 10) \\ {\rm HDL-C} \ 8.6 \pm 0.4 \ ({\rm vs.} \ 7.2 \pm 0.3) \\ \\ \hline $	
$ \begin{array}{c} \text{LDL-C } 122 \pm 15 \ (\text{vs.} 185 \pm 20) \\ \text{VLDL-C } 57 \pm 6.9 \ (\text{vs.} 81 \pm 10) \\ \text{HDL-C } 8.2 \pm 0.2 \ (\text{vs.} 7.2 \pm 0.3) \\ - \text{at dose of 100 mg/kg} \\ \text{TG } 147 \pm 25 \ (\text{vs.} 190 \pm 28) \\ \text{LDL-C } 117 \pm 17 \ (\text{vs.} 185 \pm 20) \\ \text{VLDL-C } 56 \pm 7.1 \ (\text{vs.} 81 \pm 10) \\ \text{HDL-C } 8.6 \pm 0.4 \ (\text{vs.} 7.2 \pm 0.3) \\ \end{array} \right) \\ \hline \\ \begin{array}{c} \text{c. carthagenensis} \\ (\text{infusion of herb)} \end{array}  \text{body weight consignificant } \downarrow \text{ in cholesterolemia} \\ \text{trol} \end{array}  \begin{array}{c} \text{male Wistar rats undergoing a high } \\ \text{administrated to the rats al libitor } \\ \text{trol} \end{array}  \begin{array}{c} \text{while chronic } (4 \cdot \text{weeks; infusion} \\ \text{calorie diet} \end{array}  \begin{array}{c} \text{calorie diet} \\ \text{administrated to the rats al libitor } \\ \text{trol} \end{array}  \begin{array}{c} \text{rolesterol} [mg/\text{LL}] 57 \pm 9 \ (\text{vs.} 96 \\ \pm 23) \\ - \text{ no significant effect on glycemic} \\ \\ \text{level, body weight and triglyceride} \\ \\ \text{rat a ortic rings probably associare at a ortic rings with functional at a drive of a point of the polyphenolic comparison to control group \\ \text{rat a ortic rings probably associare at ed with polyphenolic comparison to control group \\ \text{rat a ortic rings probably associare at a ortic rings with functional at a ortic rings with functional at a ortic rings probably associare at ed with polyphenolic comparison to contracted with polyphenolic comparison to calculated \\ (46.8 \pm 11.4) \\ \text{- aqueous extract } 4.92 \pm 0.11 \ (81.8 \pm 5.1) \\ \text{- aqueous extract } 4.92 \pm 0.06 \\ (86.2 \pm 1.6) \\ \text{- methanol-insoluble water frac} \\ \end{array}$	
$VLDL-C 57 \pm 6.9 (vs. 81 \pm 10)$ HDL-C 8.2 \pm 0.2 (vs. 7.2 \pm 0.3) - at dose of 100 mg/kg TG 147 \pm 25 (vs. 190 \pm 28) LDL-C 117 \pm 17 (vs. 188 \pm 20) VLDL-C 56 \pm 7.1 (vs. 81 \pm 10) HDL-C 8.6 \pm 0.4 (vs. 7.2 \pm 0.3) C. carthagenensis body weight con significant $\downarrow$ in cholesterolemia administrated to the rats ad libitum) treatment (vs. control) - cholesterol [mg/dL] 57 \pm 9 (vs. 96 \pm 23) - no significant effect on glycemic level, body weight and triglyceride level in comparison to control group C. carthagenensis (ethanol and aque- vasorelaxant (ethanol ethick (infusion (plCss)] (max vaso- dilatation [plCss)] (max vaso- dilatation $\%$ ): - ethanol extract 4.92 ± 0.11 (81.8 ± 5.1) - aqueous extract not calculated (46.8 ± 14.4) - n-butanol fraction 4.98 ± 0.06 (86.2 ± 1.6) - methanol-insoluble water frac-	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	
$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
VLDL-C 56 $\pm$ 7.1 (vs. 81 $\pm$ 10) HDL-C 8.6 $\pm$ 0.4 (vs. 7.2 $\pm$ 0.3)C. carthagenensis (infusion of herb)body weight con significant $\downarrow$ in cholesterolemia administrated to the rats ad libi- tum) treatment (vs. control) - cholesterol [mg/dL] 57 $\pm$ 9 (vs. 96 $\pm$ 23) - no significant effect on glycemic level, body weight and triglyceride level in comparison to control groupmale Wistar rats undergoing a high calorie diet administrated to the rats ad libi- tum) treatment (vs. control) - cholesterol [mg/dL] 57 $\pm$ 9 (vs. 96 $\pm$ 23) - no significant effect on glycemic level, body weight and triglyceride level in comparison to control groupC. carthagenensis (ethanol and aque- ous extracts of aerial parts and derived fractions)vasorelaxant t ated with polyphenolic com- pounds - vasodilatation [pICs0] (max vaso- dilatation %): - ethanol extract 4.92 $\pm$ 0.11 (81.8 $\pm$ 5.1) - aqueous extract not calculated (46.8 $\pm$ 14.4) - <i>n</i> -butanol fraction 4.98 $\pm$ 0.06 (86.2 $\pm$ 1.6) - methanol-insoluble water frac-	
$\begin{tabular}{ c c c c c } HDL-C 8.6 \pm 0.4 (vs. 7.2 \pm 0.3) \\ \hline HDL-C 8.6 \pm 0.4 (vs. 7.2 \pm 0.3) \\ \hline C. carthagenensis (infusion of herb) trol while chronic (4-weeks; infusion administrated to the rats ad libitum) treatment (vs. control) - cholesterol [mg/dL] 57 \pm 9 (vs. 96 \pm 23) - no significant effect on glycemic level, body weight and triglyceride level in comparison to control group \\ \hline C. carthagenensis (ethanol and aqueous extracts of aerial parts and derived fractions) & - vasodilatation [PICso] (max vaso-dilatation %): - ethanol extract 4.92 \pm 0.11 (81.8 \pm 5.1) - aqueous extract not calculated (46.8 \pm 14.4) - n-butanol fraction 4.98 \pm 0.06 (86.2 \pm 1.6) - methanol-insoluble water fraction calculated water fraction calculated (46.8 \pm 16.4) - methanol-insoluble water fraction calculated calculate$	
C. carthagenensis (infusion of herb)body weight con significant $\downarrow$ in cholesterolemia administrated to the rats ad libi- turm) treatment (vs. control) - cholesterol [mg/dL] 57 $\pm$ 9 (vs. 96 $\pm$ 23) - no significant effect on glycemic level, body weight and triglyceride level in comparison to control groupmale Wistar rats undergoing a high calorie diet administrated to the rats ad libi- turm) treatment (vs. control) - cholesterol [mg/dL] 57 $\pm$ 9 (vs. 96 $\pm$ 23) - no significant effect on glycemic level, body weight and triglyceride level in comparison to control groupC. carthagenensis (ethanol and aque- ous extracts of aerial parts and derived fractions)vasorelaxant - vasodilatation on pre-contracted ated with polyphenolic com- pounds - vasodilatation [pICso] (max vaso- dilation %): - ethanol extract 4.92 $\pm$ 0.11 (81.8 $\pm$ 5.1) - aqueous extract not calculated (46.8 $\pm$ 14.4) - <i>n</i> -butanol fraction 4.98 $\pm$ 0.06 (86.2 $\pm$ 1.6) - methanol-insoluble water frac-	
(infusion of herb) trol while chronic (4-weeks; infusion calorie diet administrated to the rats ad libi- tum) treatment (vs. control) - cholesterol [mg/dL] $57\pm 9$ (vs. 96 $\pm 23$ ) - no significant effect on glycemic level, body weight and triglyceride level in comparison to control group <i>C. carthagenensis</i> vasorelaxant (ethanol and aque- ous extracts of aerial ated with polyphenolic com- parts and derived fractions) <i>vasorelaxant</i> - vasodilatation [pICso] (max vaso- dilatation %): - ethanol extract $4.92 \pm 0.11$ ( $81.8 \pm 5.1$ ) - aqueous extract not calculated ( $46.8 \pm 14.4$ ) - <i>n</i> -butanol fraction $4.98 \pm 0.06$ ( $86.2 \pm 1.6$ ) - methanol-insoluble water frac-	
(infusion of herb) trol while chronic (4-weeks; infusion calorie diet administrated to the rats ad libi- tum) treatment (vs. control) - cholesterol [mg/dL] 57 $\pm$ 9 (vs. 96 $\pm$ 23) - no significant effect on glycemic level, body weight and triglyceride level in comparison to control group C. carthagenensis (ethanol and aque- ous extracts of aerial parts and derived fractions) Vasorelaxant - vasodilatation on pre-contracted ex vivo aortic rings with functional ated with polyphenolic com- parts and derived fractions) - vasodilatation [pIC <sub>50</sub> ] (max vaso- dilatation %): - ethanol extract 4.92 $\pm$ 0.11 (81.8 $\pm$ 5.1) - aqueous extract not calculated (46.8 $\pm$ 14.4) - <i>n</i> -butanol fraction 4.98 $\pm$ 0.06 (86.2 $\pm$ 1.6) - methanol-insoluble water frac-	[100]
administrated to the rats ad libi- tum) treatment (vs. control) - cholesterol [mg/dL] 57 $\pm$ 9 (vs. 96 $\pm$ 23) - no significant effect on glycemic level, body weight and triglyceride level in comparison to control group C. carthagenensis vasorelaxant (ethanol and aque- ous extracts of aerial parts and derived fractions) Vasodilatation [pIC <sub>50</sub> ] (max vaso- dilatation %): - ethanol extract 4.92 $\pm$ 0.11 (81.8 $\pm$ 5.1) - aqueous extract not calculated (46.8 $\pm$ 14.4) - <i>n</i> -butanol fraction 4.98 $\pm$ 0.06 (86.2 $\pm$ 1.6) - methanol-insoluble water frac-	[100]
$\begin{array}{c} \mbox{tum} \mbox{treatment (vs. control)} & - \mbox{cholesterol [mg/dL] } 57\pm 9 \ (vs. 96 \\ \pm 23) & - \mbox{no significant effect on glycemic} \\ \mbox{level, body weight and triglyceride} \\ \mbox{level, body weight and triglyceride} \\ \mbox{level in comparison to control} \\ \mbox{group} \\ \hline C. \ carthagenensis \\ \ vasorelaxant \\ \ (ethanol and aque- \\ ous extracts of aerial \\ \mbox{ated with polyphenolic com-} \\ \mbox{phenylephrine, from male Wistar r} \\ \mbox{parts and derived} \\ \mbox{fractions} \\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ $	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
$\begin{array}{c} \pm 23 \\ & \text{- no significant effect on glycemic} \\ & \text{level, body weight and triglyceride} \\ & \text{level in comparison to control} \\ & \text{group} \\ \hline C. \ carthagenensis \\ (ethanol and aque- \\ ous extracts of aerial \\ parts and derived \\ fractions) \\ \hline \end{array} \begin{array}{c} \text{- vasodilatation on pre-contracted ex vivo aortic rings with functional} \\ & \text{ated with polyphenolic com-} \\ & \text{phenylephrine, from male Wistar r} \\ & \text{pounds} \\ & \text{- vasodilatation [pICso] (max vaso-} \\ & \text{dilatation \%):} \\ & \text{- ethanol extract 4.92 \pm 0.11 (81.8 \pm \\ & 5.1) \\ & \text{- aqueous extract not calculated} \\ & (46.8 \pm 14.4) \\ & \text{- n-butanol fraction 4.98 \pm 0.06} \\ & (86.2 \pm 1.6) \\ & \text{- methanol-insoluble water frac-} \\ \hline \end{array}$	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
level, body weight and triglyceride level in comparison to control groupC. carthagenensis (ethanol and aque- ous extracts of aerial parts and derived fractions)vasorelaxant - vasodilatation on pre-contracted ex vivo aortic rings with functional endothelium, pre-contracted with phenylephrine, from male Wistar r pounds - vasodilatation [pIC50] (max vaso- dilatation %): - ethanol extract $4.92 \pm 0.11$ ( $81.8 \pm$ 5.1) - aqueous extract not calculated ( $46.8 \pm 14.4$ ) - <i>n</i> -butanol fraction $4.98 \pm 0.06$ ( $86.2 \pm 1.6$ ) - methanol-insoluble water frac-	
level in comparison to control groupC. carthagenensis (ethanol and aque- ous extracts of aerial parts and derived fractions)- vasodilatation on pre-contracted endothelium, pre-contracted with pounds - vasodilatation [pIC50] (max vaso- dilatation %): - ethanol extract $4.92 \pm 0.11$ ( $81.8 \pm$ 5.1) - aqueous extract not calculated ( $46.8 \pm 14.4$ ) - $n$ -butanol fraction $4.98 \pm 0.06$ ( $86.2 \pm 1.6$ ) - methanol-insoluble water frac-	
groupC. carthagenensisvasorelaxant- vasodilatation on pre-contractedex vivo aortic rings with functional(ethanol and aque-rat aortic rings probably associ-endothelium, pre-contracted withous extracts of aerialated with polyphenolic com-phenylephrine, from male Wistar rparts and derivedpounds- vasodilatation [pIC50] (max vaso-fractions)- vasodilatation [pIC50] (max vaso-dilatation %):- ethanol extract $4.92 \pm 0.11$ ( $81.8 \pm 5.1$ )- aqueous extract not calculated( $46.8 \pm 14.4$ )- n-butanol fraction $4.98 \pm 0.06$ ( $86.2 \pm 1.6$ )- methanol-insoluble water frac-	
C. carthagenensisvasorelaxant- vasodilatation on pre-contractedex vivo aortic rings with functional(ethanol and aque- ous extracts of aerial- vasodilatation on pre-contractedendothelium, pre-contracted withous extracts of aerialated with polyphenolic com- poundsphenylephrine, from male Wistar rparts and derived fractions)- vasodilatation [pIC50] (max vaso- dilatation %): - ethanol extract $4.92 \pm 0.11$ ( $81.8 \pm$ 5.1) - aqueous extract not calculated ( $46.8 \pm 14.4$ ) - <i>n</i> -butanol fraction $4.98 \pm 0.06$ ( $86.2 \pm 1.6$ ) - methanol-insoluble water frac-	
(ethanol and aque- ous extracts of aerialrat aortic rings probably associ- ated with polyphenolic com- poundsendothelium, pre-contracted with phenylephrine, from male Wistar r poundsparts and derived fractions)- vasodilatation [pIC50] (max vaso- dilatation %): - ethanol extract $4.92 \pm 0.11$ ( $81.8 \pm$ 5.1) - aqueous extract not calculated ( $46.8 \pm 14.4$ ) - <i>n</i> -butanol fraction $4.98 \pm 0.06$ ( $86.2 \pm 1.6$ ) - methanol-insoluble water frac-	[45]
ous extracts of aerialated with polyphenolic com- poundsphenylephrine, from male Wistar r poundsfractions)- vasodilatation [pIC50] (max vaso- dilatation %): - ethanol extract $4.92 \pm 0.11$ ( $81.8 \pm$ 5.1) - aqueous extract not calculated ( $46.8 \pm 14.4$ ) - <i>n</i> -butanol fraction $4.98 \pm 0.06$ ( $86.2 \pm 1.6$ ) - methanol-insoluble water frac-	[45]
parts and derived pounds fractions) $-$ vasodilatation [pIC <sub>50</sub> ] (max vaso- dilatation %): - ethanol extract 4.92 ± 0.11 (81.8 ± 5.1) - aqueous extract not calculated (46.8 ± 14.4) - <i>n</i> -butanol fraction 4.98 ± 0.06 (86.2 ± 1.6) - methanol-insoluble water frac-	
fractions) - vasodilatation [pIC <sub>50</sub> ] (max vaso- dilatation %): - ethanol extract $4.92 \pm 0.11$ ( $81.8 \pm 5.1$ ) - aqueous extract not calculated ( $46.8 \pm 14.4$ ) - <i>n</i> -butanol fraction $4.98 \pm 0.06$ ( $86.2 \pm 1.6$ ) - methanol-insoluble water frac-	ts
dilatation %): - ethanol extract $4.92 \pm 0.11$ ( $81.8 \pm 5.1$ ) - aqueous extract not calculated ( $46.8 \pm 14.4$ ) - <i>n</i> -butanol fraction $4.98 \pm 0.06$ ( $86.2 \pm 1.6$ ) - methanol-insoluble water frac-	
- ethanol extract $4.92 \pm 0.11$ (81.8 ± 5.1) - aqueous extract not calculated (46.8 ± 14.4) - <i>n</i> -butanol fraction $4.98 \pm 0.06$ (86.2 ± 1.6) - methanol-insoluble water frac-	
5.1) - aqueous extract not calculated $(46.8 \pm 14.4)$ - <i>n</i> -butanol fraction $4.98 \pm 0.06$ $(86.2 \pm 1.6)$ - methanol-insoluble water frac-	
- aqueous extract not calculated $(46.8 \pm 14.4)$ - <i>n</i> -butanol fraction $4.98 \pm 0.06$ $(86.2 \pm 1.6)$ - methanol-insoluble water frac-	
$(46.8 \pm 14.4)$ - <i>n</i> -butanol fraction $4.98 \pm 0.06$ $(86.2 \pm 1.6)$ - methanol-insoluble water frac-	
- <i>n</i> -butanol fraction $4.98 \pm 0.06$ (86.2 ± 1.6) - methanol-insoluble water frac-	
(86.2 ± 1.6) - methanol-insoluble water frac-	
- methanol-insoluble water frac-	
- methanol-insoluble water frac-	
tion $4.53 \pm 0.03$ (94.8 ± 4.3)	
- methanol-soluble water fraction	
$4.85 \pm 0.11 (89.1 \pm 4.5)$	
$- \text{ emulsion } 4.93 \pm 0.07 \ (86.0 \pm 7.1)$	
<i>C. carthagenensis</i> vasorelaxant - the <i>n</i> -butanol fraction induced ex vivo endothelium-intact rings of	[101]
(aqueous–ethanol- relaxation in rat aortic rings (IC <sub>50</sub> = thoracic aorta from male Wistar rat	
extract of aerial $6.85 \ \mu g/mL$ ) through two separate	
parts) mechanisms	

<i>C. carthagenensis</i> (ethanol-soluble fraction of aqueous extract from aerial parts)	cardioprotective	<ul> <li>endothelium-dependent: stimu- lation and/or potentiation of NO release and stimulation and/or po- tentiation of NO release</li> <li>endothelium-independent: free radical-scavenging properties</li> <li>inhib. of the progression of the cardiorenal disease while a 4- weeks treatment</li> <li>modulation of the antioxidant defense system</li> <li>NO/cGMP activation and K+ channel opening-dependent vaso- dilator effect</li> </ul>	female Wistar rats in vivo two-kidney, one-clip (2K1C) model	[102]
<i>C. carthagenensis</i> (aqueous–ethanol extract of leaves and <i>n</i> -butanol and ethyl acetate fractions)	antioxidant	<ul> <li>inhib. of NBT ↓ by O<sub>2</sub>-</li> <li>concentration-dependent inhib.</li> <li>of deoxyribose degradation</li> <li>inhib. of lipid peroxidation in-</li> <li>duced by <i>t</i>-butyl-peroxide</li> </ul>	in vitro xanthine/xanthine oxidase as say in vitro deoxyribose degradation as- say in vitro lipid peroxidation assay	
<i>C. carthagenensis</i> (methanol extract of leaves)	antioxidant anti-biofilm and QS-related viru- lence factors	<ul> <li>dose-dependent DPPH scavenging activity</li> <li>max activity at 1.0 mg/mL (64.79 ± 0.83%)</li> <li>↓ of ferricyanide complex (Fe<sup>3+</sup>) to the ferrous form (Fe<sup>2+</sup>)</li> <li>inhib. of biofilm formation at the concentration of 1 mg/mL by</li> <li>81.88 ± 2.57% (TCP method)</li> <li>72.14 ± 3.25% (tube method)</li> <li>inhib. of production of QS-dependent virulence factors in <i>Pseudomonas aeruginosa</i> at sub-lethal concentrations of extract without affecting bacterial growth:</li> <li>significant ↓ in pyocyanin production</li> <li>max inhib. at the concentration of 1.0 mg/mL by 84.55 ± 1.63%</li> <li>at the concentration of 0.25 mg/mL by 77.50 ± 2.10%</li> <li>inhib. of violacein production</li> </ul>	in vitro FRAP assay in vitro tissue culture plate method (TCP) in vitro tube method microscopic techniques <i>Chromobacterium violaceum</i> ATCC12472, <i>Pseudomonas aeruginosa</i> MTCC 2297	[17]
<i>C. glutinosa</i> (aqueous–ethanol extract of leaves)	antihypertensive	violaceum - ACE-inhib. activity [%] of the ex- tract of leaves collected in: - Alegrete 31.66 - Unistalda 26.32 - miquelianin 32.41	in vitro ACE-inhib.	[59]
<i>C. glutinosa</i> (aqueous and etha- nol extracts of whole plant and derived fractions)	antioxidant	<ul> <li>DPPH scavenging activity [EC<sub>50</sub> μg/mL]</li> <li>aqueous extract 64.75</li> <li>ethyl acetate fraction 16.77</li> <li>ethanolic extract 42.17</li> <li>lower antioxidant capacity compared with the standard quercetin 2.059</li> </ul>		[63]

	inhibitory activ- ity on Na <sup>+</sup> , K <sup>+</sup> -	- inhib. of the enzyme activity by	in vitro ATPase extracted from male Wistar rat heart muscle membranes	
	ATPAse	the ethanolic extract at the concentra- tion above 100 $\mu$ g/mL with EC <sub>50</sub> = 84.54 (48.77 to 146.6) $\mu$ g/mL		
<i>C. glutinosa</i> (roots and leaves in-	antifungal	<ul> <li>MIC [μg/mL] values:</li> <li>roots infusion</li> <li>Trichemory grahii TBE 23.7.8</li> </ul>	in vitro broth microdilution method <i>Trichosporon asahii</i> TBE 23, <i>T. asahii</i> TAH 09, <i>Candida naranciloris</i> BL 36, <i>C</i>	
fusions and macera- tions)		Trichosporon asahii TBE 23 7.8T. asahii TAH 09 1.9Candida parapsilosis RL 36 15.9C. parapsilosis RL 07 62.5Candida glabrata CG 08 >500C. glabrata CG 10 >500Candida tropicalis 102 A 62.5C. tropicalis 72 A 62.5- leaf infusionTrichosporon asahii TBE 23 1.9T. asahii TAH 09 1.9Candida glabrata CG 08 >500C. glabrata CG 10 >500Candida parapsilosis RL 36 7.8C. parapsilosis RL 07 31.25Candida glabrata CG 08 >500C. glabrata CG 10 >500Candida tropicalis 102 A 62.5C. tropicalis 72 A 62.5- root macerationTrichosporon asahii TBE 23 3.9T. asahii TAH 09 15.6Candida parapsilosis RL 36 62.5C. parapsilosis RL 07 62.5Candida glabrata CG 08 >500C. glabrata CG 10 >500Candida parapsilosis RL 36 62.5C. parapsilosis RL 07 62.5Candida parapsilosis RL 36 62.5C. glabrata CG 10 >500Candida parapsilosis RL 36 62.5C. glabrata CG 10 >500Candida parapsilosis RL 36 62.5C. tropicalis 72 A 62.5- leaf macerationTrichosporon asahii TBE 23 1.9T. asahii TAH 09 500Candida parapsilosis RL 36 31.25C. parapsilosis RL 07 31.25	TAH 09, Candida parapsilosis RL 36, C. parapsilosis RL 07, C. glabrata CG 08, C. glabrata CG 10, C. tropicalis 102 A, C. tropicalis 72 A	
		<i>Candida glabrata</i> CG 08 62.5 <i>C. glabrata</i> CG 10 >500		
		<i>Candida tropicalis</i> 102 A 15.6 <i>C. tropicalis</i> 72 A 15.6		
<i>C. hyssopifolia</i> (aqueous–methanol extract)	antioxidant	- inhib. of DPPH radical at 95.5% (IC <sub>50</sub> =12.34 $\mu$ g/mL) compared to ascorbic acid—at 98.35% (IC <sub>50</sub> = 1.82 $\mu$ g/mL)	in vitro DPPH assay	[48]
<i>C. hyssopifolia</i> (methanol extract of leaves)	hepatoprotective	- changes in SOD, CAT, and MDA	in vivo paracetamol-induced hepato-	[104]

		CAT $1.80 \pm 0.01$ (vs. $0.45 \pm 0.09$ )	
		MDA 0.45 ± 0.04 (vs. 0.72 ± 0.07)	
<i>C. ignea</i> (aqueous–ethanol extract of aerial parts)	antitumor	- pre-treatment with <i>C. ignea</i> ex- tract was more effective then post- treatment and provided chemo- preventive effect probably due to its potential to attenuate benzo( $\alpha$ )pyrene-induced oxidative stress in the lung tissues through the amelioration of the antioxidant defense system	
C. ignea	antiulcerogenic,	- doses of 250 and 500 mg/kg bw	adult female Sprague-Dawley rats [58]
(aqueous–ethanol extract of aerial parts)	-	administrated orally a week before ulcer induction, decreased the vol- ume of gastric juice and gastric ul- cer index, increased gastric pH value and pepsin activity - anti-ulcer activity comparable to that of ranitidine - anti-inflammatory, antioxidant,	ein vivo ethanol-induced gastric ulcers in rats
		and curing effect on the hemor-	
		rhagic shock induced by ethanol	
C. ignea	antihypertensive	toxicity - ACE inhib. activity IC50 [mg/mL]	in vitro ACE inhib. [54,
(aqueous and etha- nol extracts of leaves, flowers, stems;	uning percensive	<ul> <li>- aqueous extract of leaves 0.491</li> <li>- ethanolic extract of leaves 2.151</li> <li>- ethanolic extract of the flowers</li> <li>1.748</li> </ul>	]
<i>n</i> -butanol and ethyl acetate fractions)		<ul> <li>aqueous extract of stems 2.036</li> <li>ethanolic extract of stems 5.707</li> <li><i>n</i>-butanol fraction of ethanol extract of leaves 0.084</li> <li>ethyl acetate fraction of ethanol extract, of leaves 0.215</li> </ul>	
		extract. of leaves 0.215	in vitro renin inhib.
		<ul> <li>inhib. of renin activity [%] at the sample concentration of 10 mg/mL</li> <li>ethanolic extract of leaves 94.82</li> <li>ethanolic extracts of stems 88.98</li> <li>ethanolic extract of flowers 86.65</li> <li>methylene chloride of the stems 98.14</li> </ul>	
		- ethyl acetate fractions of leaves 93.09	male Sprague-Dawley rats in vivo L-NAME-induced hyperten- sion model
		- attenuation of elevated systolic blood pressure by ethanolic ex- tract of leaves (at doses of 250 and 500 mg/kg b.wt.) similarly to standard lisinopril	
<i>C. ignea</i> (hydrolyzed seed oil)	antibacterial	- MIC [mg/mL] values: Enterococcus cecorum CCM 3659 2.25 CCM 4285 1.13 Clostridium perfringens CIP 105178 0.56 CNCTC 5454 4.5 UGent 56 2.25	in vitro broth microdilution method [43] Enterococcus cecorum CCM 3659, CCM 4285 Clostridium perfringens CIP 105178, CNCTC 5454, UGent 56 Lis- teria monocytogenes ATCC 7644 Staph- ylococcus aureus ATCC 25923 Bifidobac- terium animalis CCM 4988, MA5 B. longum TP 1, CCM 4990 Lactobacillus

		Listeria monocytogenes ATCC 7644 1.13 Staphylococcus aureus ATCC 25923 2.25	fermentum CCM 91 L. acidophilus CCN 4833	1
<i>C. ingrata</i> (5% tincture)	hypocholestere- mic	<ul> <li>significant cholesterol level ↓, no significant effect on cholesterol ab- sorption and triglyceride profile</li> </ul>	in vivo male mice diet-induced hy- percholesterolemia model	[107]
<i>C. ingrata</i> (methanol extract of aerial parts)	antimicrobial	<i>- B. cereus</i> and <i>C. albicans</i> growth inhib. with MIC 39 μg/mL	in vitro serial dilution assay Bacillus cereus, Candida albicans	[55]
<i>C. ingrata</i> (dichloromethane– methanol (1:1) and ethanol extracts of aerial parts)	trypanocidal	<ul> <li>- 29% inhib. at a concentration of 100 μg/mL of the dichloro- methane-methanol (1:1) extract</li> <li>- no effect of the aqueous extract</li> </ul>	in vitro epimastigote assay <i>Trypanosoma cruzi</i>	[108]
<i>C. lindmaniana</i> (aqueous–ethanol extract of leaves)	anti-inflamma- tory	- 100% PMNs migration inhib. at the concentrations of 0.01–10.0 $\mu$ g/mL of the extract	in vitro inhib. of rat PMNs chemo- taxis, employing a modified Boyden chamber	[66]
<i>C. pinetorum</i> (dichloromethane– methanol extract of aerial parts)	antihypertensive antiprotozoal	<ul> <li>ACE-inhib. activity 19.58%</li> <li>inhib. of the growth of trophozo- ites by isolated flavonoids with kaempferol as the most active compound against <i>E. hystolitica</i> (IC<sub>50</sub>=7 μg/mL) and <i>G. lamblia</i> (IC<sub>5</sub> = 8.7 μg/mL)</li> </ul>	in vitro ACE-inhib. in vitro susceptibility test using a sub culture method <i>Entamoeba histolytica</i> HM1-IMSS, <i>Giardia lamblia</i> IMSS:0989:1	9-[69]
C. pinetorum (isolated flavonoids)	antiprotozoal	- antiprotozoal activity of isolated	suckling female CD-1 mice in vivo experimental infection of <i>Gi</i> - ardia lamblia	[109]
<i>C. pinetorum</i> (methanol extracts o stems and leaves)	antimicrobial f	- inhib. effect of the extracts at dose of 10 mg on <i>S. aureus</i> and <i>C. albicans</i>	in vitro disc-diffusion method <i>Staphylococcus aureus</i> ATCC 15006, <i>Candida albicans</i> ATCC 10231	[110]
<i>C. subuligera</i> (methanol extract of stems)	antimicrobial	- inhib. effect of the extract at dose of 10 mg on <i>S. aureus</i> (significant) and <i>C. albicans</i>	in vitro disc-diffusion method <i>Staphylococcus aureus</i> ATCC 15006, <i>Candida albicans</i> ATCC 10231	[110]
<i>C. urbaniana</i> (aqueous–ethanol extract of leaves col- lected in	anti-inflamma- tory	- 100% PMNs migration inhib. at the concentrations of 0.001–10.0 μg/mL of the extract	in vitro inhib. of rat PMNs chemo- taxis, employing a modified Boyden chamber.	[66]
	santihypertensive	<ul> <li>ACE-inhib. activity [%] of the extract of leaves collected in:</li> <li>Unistalda 22.82</li> <li>Barros Cassal 22.29</li> </ul>	in vitro ACE-inhib.	
	ABTS vertir FRAF MDA sorba lipase	—2,2'-azino-bis(3-ethylbenzothiazo ng enzyme; CAT—catalase; DP P—ferric reducing antioxidant powo —malondialdehyde; NBT—nitro-b nce capacity; PMNs—polymorphon p; QS—quorum sensing; ROS—rea	itory; $\downarrow$ —decrease/reduction; $\uparrow$ —ir oline-6-sulfonic acid); ACE—angiotens PH—2,2-diphenyl-1-picrylhydrazyl er; IL—interleukin; LPS—lipopolysacc due tetrazolium; ORAC—oxygen rad nuclear neutrophils; PPL—porcine par ctive oxygen species; SOD—superoxi idant capacity; TNF- $\alpha$ —tumor necrosi	in-con- radical; haride; ical ab- ncreatic de dis-

α.

#### 5.1. Hypotensive Activity of Cupheas

One of the most studied folk medicinal *Cuphea* species is *C. carthagenensis*, known as Colombian waxweed. Whole plants or aerial parts are commonly used as antihypertensives [76,103,111]. The species is also an antinociceptive, antiviral, antimicrobial, anti-inflammatory, and weight-reducing agent [112]. The in vitro ACE (angiotensin converting enzyme) inhibitory activity of an ethanolic leaf extract obtained from *C. carthagenensis* was determined by Santos et al. [59]. The extract, at a concentration of 100 ng/mL, reduced the enzyme activity by 32.41%. Other reports on the pharmacological activity of *C. carthagenensis* (Table 4) confirmed its cardioprotective, hypolipidemic, and antioxidant properties [17,45,79,101–103]. The data from these studies showed that the traditional use of this plant in the treatment of cardiovascular problems is well founded.

In vitro ACE inhibitory properties were also reported for C. urbaniana Koehne leaf extracts collected in Unistalda and Barros Cassal [66]. Compared to C. carthagenensis, they were less effective—at a concentration of 100 ng/mL, they inhibited the enzyme by 22.82% (Unistalda) and 22.29% (Barros Cassal). C. glutinosa is another species known for its hypotensive activity [63]. The plant is used in traditional Brazilian medicine to treat various cardiovascular problems: abnormal heart rhythms, heart failure, hypertension, and atherosclerosis. Santos et al. [59] demonstrated the in vitro ACE inhibitory properties of extracts (at a concentration of 100 ng/mL) from C. glutinosa leaves collected in Alegrete (31.66%) and Unistalda (26.32%). The authors found that the inhibition of the enzyme was related to the presence of miquelianin (quercetin 3-O-glucuronide) and other phenolic compounds. The isolated miquelianin at a concentration of 100 ng/mL showed ACE-inhibitory properties of 32.41%. Another *Cuphea* species with in vitro ACE inhibitory activity is *C. ignea*—"the cigar plant" native to Mexico [54]. Ismail et al. [54] noted that the *n*butanol and ethyl acetate fractions of the C. ignea leaf extract showed higher ACE inhibitory activity than the parent ethanolic extract: IC<sub>50</sub> 0.084, 0.215 and 2.151 mg/mL, respectively.

However, not all studies confirm the antihypertensive effect of traditional *Cuphea* remedies. For example, an ethanol-soluble fraction obtained from an infusion of *C. calophylla* leaves and stems did not induce any pharmacological effects in rats (diuretic, hypotensive) after 7 days of administration [62]. However, a significant antioxidant effect was observed.

When considering the use of *Cuphea* extracts in the treatment of cardiovascular conditions, the risk of interactions with other drugs used or being investigated for use in the treatment of hypertension should be taken into account. Schuldt et al. [101] demonstrated that two possible mechanisms of the in vitro vasodilatory activity of an ethanolic extract of *C. carthagenensis* are involved: endothelium-dependent mechanism of action, which depends on the nitric oxide (NO')-cyclic guanosine 3', 5'-monophosphate (cGMP) signaling, and an endothelium-independent mechanism (at higher doses;  $\geq$ 100 µg/mL). Currently, the enzymes of the NO-cGMP signaling cascade are the identified drug targets in clinical trials of novel antihypertensive drugs [113]. Should such acting drugs be introduced into clinics, the possibility of synergism with *Cuphea* extracts will need to be considered. A similar caution extends to interactions between clinically used ACE inhibitors and compounds with such activity confirmed in pharmacological studies that are present in *Cuphea* extracts, namely miquelianin and other phenolic compounds [114].


#### 5.2. Anti-Inflammatory Activity of Cupheas

Several *Cuphea* species (*C. aequipetala*, *C. calophylla*, and *C. racemosa*) have shown anti-inflammatory effects in vitro and in vivo (Figure 9). *C. aequipetala*,

commonly known as *hierba del cáncer*, cancer weed, and blow weed, is a perennial herb widely distributed in Mexico and is one of the few *Cupheas* found from Coahuila, Mexico, to Honduras [18,115]. Its leaves and stems are used to reduce fevers associated with measles and smallpox, as well as to treat inflammatory diseases or cancer [60,91,93,98]. The results of in vitro and in vivo studies of ethanolic extracts from the leaves and stems of *C. aequipetala* (Table 4) confirmed their anti-inflammatory activity, associated with up-regulation of IL-10 and down-regulation of IL-1 $\beta$ , IL-6, TNF- $\alpha$ , and PGE2 secretion [91].

The aqueous leaf extract of *C. calophylla*, as well as the isolated miquelianin, led to 100% inhibition of PMN migration at a concentration of 10 mg/mL. In contrast, *C. racemosa* extract had the same effect already at concentrations of 0.1, 0.01, and 0.001 mg/mL [96]. However, miquelianin alone does not have the potential to inhibit LPS-induced neuroinflammation, as it did not suppress the cytokine cascade and the release of IL-1 $\beta$  and TNF- $\alpha$ —proinflammatory cytokines responsible for the secretion of various pro-inflammatory mediators [116]. In contrast, 50% and 70% acetone extracts of the aerial parts of *C. carthagenensis* at a concentration of 500 µg/mL showed a significant inhibitory effect on TNF- $\alpha$  production in LPS-stimulated THP-1 monocytic cells (96.4 ± 0.2% and 99.9 ± 0.1%, respectively) [117]. An ethanolic extract of the same plant at a concentration of 62.5 µg/mL showed an inhibitory effect of 25.7 ± 0.6% on TNF- $\alpha$  release [118]. More importantly, higher concentrations of the extract (125 and 250 µg/mL) displayed lower inhibitory activity (9.8 ± 4.8% and 15.7 ± 3.0%, respectively).

Mousa et al. [58] have demonstrated the in vivo gastroprotective activity of an aqueous–ethanolic extract of aerial parts of *C. ignea*. At doses of 250 and 500 mg/kg, a significant decrease in gastric ulcer index was observed. In addition, the extract increased the pH value and decreased gastric volume. In an in vivo study, Madboli et al. [119] observed that, after a one-week treatment with *C. ignea* extract given before ethanol application, NF-kB synthesis increased, thus providing protection against EtOH toxicity.



**Figure 9.** Mechanism of anti-inflammatory and antioxidant activity of *Cuphea* extracts.

#### 5.3. Antiparasitic, Antibacterial, and Antiviral Effects

Some species of *Cupheas* are used to control parasitic infections, which are a serious problem in tropical and subtropical regions. A decoction prepared from the aerial parts of *C. pinetorum* Benth., known as *Bakmomol* and *Vach'vet* by the Tzeltal and Tzotzil Indians, is used in traditional Mayan medicine as an antidiarrheal and to treat dysentery [69]. The aerial parts and the whole plant of *C. ingrata* are used to potentiate the antimalarial activity of extracts from other plant species [120]. *C. ingrata* is also used in the treatment of syphilis and other venereal diseases [120]. Another species used against syphilis is *C. dipetala*, which grows naturally in central Colombia. In addition, this plant is also used as an astringent against oral and skin infections [121].

In a study of Hovoraková et al. [43], hydrolyzed *C. ignea* seed oil, which contains a high amount of capric acid, showed antibacterial activity against some pathogenic Gram-positive strains with an MIC value of 0.56–4.5 mg/mL. Most importantly, this hydrolyzed oil was not active toward beneficial commensal bacteria.

Cc-AgNPs (silver nanoparticles synthesized by green chemistry using an aqueous extract of *C. carthagenensis* leaves as a reducing agent) showed strong antibacterial activity against Gram-positive and Gram-negative bacteria with the lowest MIC (15  $\mu$ g/mL) and MBC (25  $\mu$ g/mL) values for *Salmonella typhimurium* [122]. AgNPs obtained using an aqueous extract of the leaves of *C. procumbens* were active against *Escherichia coli* and *Staphylococcus aureus*, with maximum inhibition zone at the concentration of 0.225 and 0.158  $\mu$ g/mL, respectively [123].

A study by Andrighetti-Fröhner et al. [124], evaluated the antiviral activity of fractions derived from a hydroethanolic extract of aerial parts of C. car*thagenensis*. The ethyl acetate, dichloromethane and *n*-butanol fractions were active against herpes simplex virus type 1 (HSV-1) strain KOS with EC50 (concentration required to inhibit viral cytopathic effect by 50%) values of 2  $\mu$ g/mL, 4  $\mu$ g/mL and 31  $\mu$ g/mL, respectively. On the other hand, the fractions were inactive against the 29-R-acyclovir-resistant HSV-1 strain and the type 2 poliovirus (PV-2), a Sabin II vaccine strain. It should be noted that Mahmoud et al. [64] recently demonstrated antiviral activity of C. ignea formulations against SARS-CoV-2. Both the polyphenol-rich ethanolic leaf extract dissolved in DMSO and the self-nanoemulsifying formulation (composed of 10% oleic acid, 40% Tween 20 and propylene glycol 50%) showed antiviral activity with IC<sub>50</sub> values of 2.47 and 2.46 µg/mL, respectively. The C. ignea extract in the developed formulation reduced virus replication by 100% at a concentration of 5.87 µg/mL, obtained from dose-response measurements. The anti-SARS-CoV-2 activity of the ethanolic extract of C. ignea could be attributed to polyphenolic compounds, of which rutin, myricetin-3-O-rhamnoside, and rosmarinic acid showed the highest antiviral potential.

#### 5.4. Antioxidant Activity

As mentioned above, *Cupheas* are rich in polyphenols that are wellknown natural antioxidants [27]. For this reason, many studies have focused on the in vitro antioxidant activity of *Cuphea* plants [16,17,48,52,63,92,103]. The results of these studies are presented in Table 4. Most studies provide data on the radical scavenging properties of alcoholic or aqueous–ethanol extracts. Among these, several reports have shown that extracts from various organs of *C. aequipetala*, *C. carthagenensis*, *C. calophylla*, and *C. hyssopifolia* showed free radical scavenging activity against DPPH [16,17,48,63,92,97]. Recently, the antioxidant activity of methanolic extracts of the leaves of *C. carthagenensis*-was also confirmed by the reduction of the ferricyanide complex (Fe<sup>3+</sup>) to the ferrous form (Fe<sup>2+</sup>) in the FRAP assay [17].

It should be noted that some *Cuphea* species possess the ability not only to scavenge free radicals, but also to inhibit the production of reactive oxygen species (ROS). For example, an ethanolic aqueous extract of the aerial parts of *C. calophylla* was found to significantly reduce ROS levels (26.2%) in LPS-induced macrophages (Figure 9) [52].

It is known that overproduction of ROS can be detrimental to biomolecules and cell membranes. An aqueous—ethanolic extract and the ethyl acetate fraction of *C. glutinosa* reduced lipoperoxidation in rat brain homogenates induced by the pro-oxidant agents: sodium nitroprusside and hydrogen peroxide [63].

As indicated by most authors, the high antioxidant activity of *Cuphea* plant extracts is closely related to their high content of polyphenols.

#### 5.5. Cytotoxic Activity of Cuphea Plants

*C. hyssopifolia,* a native plant of Mexico and Guatemala, known as false heather, has attracted much attention, mainly due to the presence of oligomeric tannins with reported cytotoxic activity. Chen et al. [125] isolated seven hydrolysable tannins, including cuphiins D<sub>1</sub> and D<sub>2</sub>, oenothein B, and woodfordin, which have since been extensively studied. Their in vitro cytotoxic activity against various human cancer cell lines (KB, HeLa, DU145, and Hep3B; Table 5) has been demonstrated [51]. It should be noted that all compounds tested were less cytotoxic than adriamycin against a normal cell line (WISH). Furthermore, all of these ellagitannins inhibited the viability of S-180 tumor cells, not only in vitro, but also *in vivo*. Oenothein B showed the highest cytotoxic activity in vitro (IC<sub>50</sub> = 11.4 µg/mL), while cuphiin D<sub>1</sub> prolonged the survival (%ILS = 84.1) of S-180 tumor-bearing ICR mice. Despite the cytotoxic potential of isolated compounds, extracts of *C. hyssopifolia* showed only moderate activity [48,126]. An aqueous methanolic extract of the aerial parts demonstrated cytotoxicity against MCF-7, Hep2, HCT-116 and HepG2 cell lines with IC<sub>50</sub> 92.5, 84.9, 81, and 73.4 µg/mL, respectively [48].

Polyphenol rich *n*-butanol and ethyl acetate fractions, obtained from the methanolic extract of the aerial parts of *C. ingrata*, showed cytotoxic effects in several human melanoma cell lines (A375, HTB-140, WM793) [127]. It should be noted that their effect on highly metastatic HTB-140 melanoma cells was greater compared to doxorubicin. However, quantitative analysis showed that the observed activity was not related to the oenothein B content, either in the extract or in the fractions. Oenothein B alone showed moderate activity against human skin and prostate cancer cell lines (DU145, PC3).

Antiproliferative and apoptotic activities of methanolic and aqueous extracts of *C. aequipetala* have been reported for several cancer cell lines: B16F10, HepG2, and MCF-7 [128]. The methanolic extract induced cell accumulation in G1 phase, DNA fragmentation, and increased caspase-3 activity in B16F10 cells in vitro. In vivo experiments showed that the aqueous extract administered per os to C57BL/6 female mice for 14 days after melanoma induction had greater antitumor activity than the methanolic extract (tumor size reduction of up to 80% and 31%, respectively).

Data referring to cytotoxic activity are summarized in Table 5.

Cuphea Species/Positive Control	Cell Line *	Cytotoxic Activity	Assay	References
C. aequipetala		ED50 [µg/mL]	Sulforhodamine B assay	[129]
(acetone-aqueous extract of the whole	HEp-2 HCT-15	>50		
plant)	DU145	18.70		
	HEp-2 HCT-15	8.1		
Colchicine	DU145	< 0.006		
		0.006		
		0.099		
C. aequipetala		% inhibition at the conc.	of 6.25 Not mentioned	[130]
(chloroform extract of aerial parts)		µg/mL		
	HeLa	$36.47 \pm 4.04$		
	DU145	$23.16 \pm 9.21$		
C. aequipetala		ED50 [µg/mL]	Oyama and Eagle method	1 [93]
(methanol extract from leaves, flowers and stems)	UISO-SQC1	17.4		
C. aequipetala		CC50 [mg/mL]	MTT assay	[128]
(aerial parts)	B16F10	0.269		
(a) methanol extract	HepG2	0.145		
	MCF-7	0.096		
	B16F10	0.364		
(b) aqueous extract	HepG2	0.212		

Table 5. In vitro cytotoxic activity of Cuphea plants.

	MCF-7	0.173		[40]
C. hyssopifolia		IC <sub>50</sub> [µg/mL]	Sulforhodamine B assay	[48]
(aqueous-methanol extract of aerial parts		92.5		
	HEp-2	84.9		
Doxorubicin	HCT-116	81.0		
(positive control)	HepG2	73.4		
	MCF-7	0.7.5		
	HEp-2	3.7–5		
	HCT-116			
	HepG2			110(1
C. hyssopifolia		EC50 [μg/mL]	MTT assay	[126]
(methanol extract)	MK-1	50-100		
(a) aerial parts	HeLa	25-50		
	B16F10	50-100		
	MK-1	25–50		
(b) roots	HeLa	50-100		
	B16F10	50–100		
Compounds isolated from <i>C. hyssopifolia</i>		IC50 [µg/mL]	MTT assay	[51]
Cuphiin D1	KB	20.0		
	DU145	51.4		
	HeLa	36.5		
	Hep3B	54.2		
	S-180	39.2		
Cuphiin D <sub>2</sub>	WISH	100.0		
	KB	20.7		
	DU145	74.0		
	HeLa	28.5		
	Нер3В	55.0		
	S-180	24.5		
Oenothein B	WISH	69.0		
	KB	26.8		
	DU145	54.5		
	HeLa	29.0		
	Нер ЗВ	19.0		
	S-180	11.4		
Woodfordin C	WISH	67.2		
	KB	28.9		
	DU145	70.5		
	HeLa	34.1		
	Нер ЗВ	34.0		
	S-180	24.7		
Adriamycin	WISH	102.5		
(positive control)	KB	<0.15		
	DU145	<0.15		
	HeLa	<0.15		
	Нер3В	<0.15		
	S-180	<0.15		
	WISH	<0.15		
Compound isolated from C. hyssopifolia		IC50 [µM]	MTT assay	[131]
Cuphiin D <sub>1</sub>	HL-60	16		[-01]
	111-00		MTT	[105]
C. <i>ignea</i> (aqueous–ethanol extract of aerial parts)	4 5 4 0	IC50 [µg/mL]	MTT assay	[105]
aqueous-emanor extract of aerial parts)	A349	376	NRU assay	
(1				

C. ignea		IC50 [µg/mL]	NRU assay	[57]
(aqueous-ethanol extract of whole plant)	nt) HaCaT	$397.34 \pm 19.83$		
	HCT-116	$70.88 \pm 0.62$		
	HuH-7	$98 \pm 2.91$		
	MRC-9	$83.65 \pm 13.43$		
	NCI-H460	$37.76 \pm 3.41$		
	NCI-H23	$32.44 \pm 5.23$		
7-hydroxy 3-methoxy coumarin	HaCaT	$220.52 \pm 28.83$		
5- <i>O</i> -β-glucopyranoside	HCT-116	$59.29 \pm 6.21$		
	HuH-7	$66.39 \pm 2.39$		
	MRC-9	$340.67 \pm 22.21$		
	NCI-H460	$45.56 \pm 1.61$		
	NCI-H23	$40.38 \pm 2.75$		
C. ingrata		IC50 [µg/mL]	LDH assay	[127]
(methanol extract of the aerial parts)	A375	36.07	-	
	HTB-140	>100		
	WM793	43.37		
	HaCaT	9.18		
	DU145	>100		
	PC3	>100		
(ethyl acetate fraction)	PNT2	>100		
	A375	15.90		
	HTB-140	3.40		
	WM793	18.75		
	HaCaT	6.12		
	DU145	>100		
	PC3	>100		
( <i>n</i> -butanol fraction)	PNT2	>100		
	A375	22.60		
	HTB-140	5.65		
	WM793	29.39		
	HaCaT	7.23		
	DU145	>100		
	PC3	>100		
Doxorubicin	PNT2	>100		
(positive control)	A375	0.59		
(,	HTB-140	5.71		
	WM793	>40		
	HaCaT	4.68		
	DU145	3.18		
	PC3	>50		
	PNT2	1.38		
C. procumbens		IC50 [µg/mL]	MTT assay	[123]
(aqueous extract of leaves)	MCF-7	>100	,	
	MDA-MB-468	>100		
	A375	>100		
	HCT-116	>100		

\* human cancer cell lines: breast: MCF-7, MDA-MB-468; cervix: HeLa, KB (a subline of the ubiquitous KERATIN-forming tumor cell line HeLa), UISO-SQC1; colon: HCT-116, HCT-15; larynx: HEp-2; leukemia: HL-60; liver: Hep3B, HepG2, HuH-7; lung: A549, NCI-H23, NCI-H460; melanoma: A375, HTB-140, WM793; prostate: DU145, PC3; stomach: MK-1; human normal cell lines keratinocytes: HaCaT; fibroblasts: MRC-9; amniotic epithelial cells: WISH (HeLa derivative); prostate epithelial cells: PNT2; animal cancer cell lines: murine melanoma: B16F10, murine sarcoma S-180. In addition to the previously mentioned possible interactions associated with the concomitant use of *Cuphea* extracts and blood pressure-lowering drugs, there are a number of other possible effects associated with the use of plant preparations. Particular attention should be paid to the polyphenolic compounds contained in them, for which agonistic or antagonistic effects towards nuclear receptors involved in xenobiotic metabolism have been repeatedly reported [132,133]. Interactions with the pregnane X receptor (PXR), constitutive androstane receptor (CAR), and aryl hydrocarbon receptor (AhR) are of particular relevance. It seems that at the cellular level, the effects induced by phytochemicals appear to be dual. On one hand, these compounds behave as agonists as they bind to the ligand-binding domain of the PXR; thereby, they can increase the transcriptional activity of downstream genes, especially CYP3A4, CYP2B, CYP2C, glutathione S-transferases, sulfotransferases, UGT, and drug transporters (OATP2, MDR1, MRP2 and MRP3) [132]. On the other hand, they may act as antagonists, either by inhibiting PXR transcription or by binding to the posttranslational active sites of mature CYPs to inhibit their catalytic activity.

#### 6. Cuphea for Commercial Use

Plants of the Cuphea genus are of great interest, not only owing to their therapeutic value, but also their potential for non-medical use. Due to their ability to synthesize MCFAs, they are valuable crops for the chemical, cosmetic and food industries. Cuphea oils are used in the production of detergents, surfactants, anti-foaming agents, etc. [19]. Cuphea viscosissima seed oil (INCI), in cosmetic products, acts as a hair and skin conditioner, while Cuphea lanceolata/viscosissima seed oil (INCI) is used as a skin conditioneremollient. Cuphea oil can be an ingredient in decorative cosmetics (e.g., lipsticks), bodycare products (bath oils and creams) or hair-care cosmetics (lotions) [134]. Oils with high levels of decanoic acid, due to cross ketonisation reactions with acetic acid, are used in the production of 2-undecanone, which is a well-known aromatic compound and an insect repellent [135]. Cuphea oils are being investigated as a source of biobased lubricants [136]. Estolides synthesized by the reaction of *Cuphea* fatty acids with oleic acid (especially oleicoctanoate and oleic-decanoate estolide 2-ethyl esters) showed better lubricating properties than other vegetable oils [137,138]. In the food industry, Cuphea oil is used in the chewing gum manufacturing process instead of saturated fats and plasticizers such as glycerol. The oil is also used as a solvent and a release agent in the manufacture of candies.

The production of *Cuphea* seed oils generates significant amounts of by-products [139]. These are being considered as potential commercial plant growth regulators. Oil cake and pressing residues can be used as organic fertilizers and soil improvers. *Cuphea* seed oil fractions are potential biodegradable 'environmentally friendly' herbicides.

In addition, *Cuphea* seed oil can be used in the production of biodiesel and aviation fuel [140]. As a jet fuel additive, it can lower the fuel's freezing point.

# 7. Methods

Relevant information on the genus *Cuphea* was collected through electronic databases, including Scopus, PubMed, Web of Science, Google Scholar, ProQuest and other professional websites. Plant names were verified by The Plant List Database (http://www.theplantlist.org/, accessed on 12 September 2022).

#### 8. Conclusions

*Cuphea* P. Browne is the largest genus of the Lythraceae family, comprising mainly herbs and shrubs typical of the warm temperate to tropical regions of the American continent. Several species, especially *C. carthagenensis* and *C. aequipetala*, are popular traditional medicines from which herbal teas, infusions, and decoctions are prepared. Diseases most commonly treated with *Cuphea* extracts include hypertension, gastrointestinal disorders, rheumatism, or infections.

Despite the wide use of *Cuphea* species in traditional medicine, the scientific literature provides relatively few pharmacological studies. However, data from these studies have shown that the traditional use of some species in the treatment of hypertension, inflammatory conditions, or parasitic infections is well supported. Alcoholic, hydroalcoholic, and water extracts are more frequently used in pharmacological studies than isolated fractions. Often, however, the phytochemical profile of the extracts studied is unknown. In recent years, however, there has been a rapid increase in the number of published reports on *Cuphea* species.

Initially, research focused on *Cuphea* seed oils, which contain medium-chain fatty acids, as potential replacements for coconut and palm oils. Today, *Cuphea* seed oils have gained particular attention as a source of biodiesel fuels and other industrial bioproducts. Therefore, the domestication of *Cuphea* plants suitable for large-scale cultivation is the subject of intensive agricultural research. Recent phytochemical studies of *Cuphea*s have shown that these plants can be a rich source of various polyphenolic compounds: flavonoids, tannins, phenolic acids, and their derivatives, which are responsible for the hypotensive, antiparasitic, antiviral, and cytotoxic activity of *Cuphea* extracts, among others. However, further pharmacological research on *Cupheas* is undoubtedly needed to verify their biological effects and safety under in vivo conditions.

**Author Contributions:** Conceptualization, D.S., K.M. and I.P.; methodology, D.S. and K.M.; investigation, D.S., D.W.-B. and K.G.; resources, D.S.; writing—original draft preparation, D.S., K.M., I.P., D.W.-B. and K.G.; writing—review and editing, D.S., K.M., I.P., D.W.-B., K.G., M.A.O. and A.O.-J.; visualization, K.M. and D.W.-B.; supervision, I.P. and M.A.O. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Jagiellonian University, Medical College, project number N42/DBS/000204 and Medical University of Lodz, grant number 503/3-022-01/503-31-001.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

# References

- 1. Graham, S.A. Cuphea: A new plant source of medium-chain fatty acids. Crit. Rev. Food Sci. Nutr. 1989, 28, 139–173.
- Barber, J.C.; Ghebretinsae, A.; Graham, S.A. An expanded phylogeny of *Cuphea* (Lythraceae) and a North American monopoly. *Plant Syst. Evol.* 2010, 289, 35–44.
- Graham, S.A.; Freudenstein, J.V.; Luker, M. A phylogenetic study of *Cuphea* (Lythraceae) based on morphology and nuclear rDNA ITS sequences. Sys. Bot. 2006, 31, 764–778.
- 4. Brauner, L.M.; Cavalcanti, T.B. A new species, a new synonym and lectotypification in *Cuphea* (Lythraceae) from Brazil. *Phytotaxa* **2018**, *350*, 155–160.
- 5. Graham, S.A. A revision of Cuphea section Amazoniana s.s. (Lythraceae). Sys. Bot. 2019, 44, 146–183.
- Graham, S.A.; Cavalcanti, T.B. Taxonomic revision of *Cuphea* sect. *Euandra* subsect. *Oidemation* (Lythraceae). *Phytotaxa* 2013, 113, 1–86.
- Cavalcanti, T.B.; Graham, S.A.T.; Facco, M.G.; Brauner, L.M. Cuphea. Flora e Funga do Brasil. Jardim Botânico do Rio de Janeiro. Available online: https://floradobrasil.jbrj.gov.br/FB8735 (accessed on 30 June 2022).
- 8. Cavalcanti, T.B. Flora da Serra do Cipo, Minas Gerais: Lythraceae. *Bolm. Botânica* **1990**, *12*, 67–93.
- 9. El Bassam, N., (Ed.); Energy plant species. *Cuphea*. In *Energy Plant Species: Their Use and Impact on Environment and Development,* 1st ed.; James and James (Science Publishers) Ltd.: London, UK, 1998; pp. 137–140.
- 10. African Plant Database (version 4.0.0). Conservatoire et Jardin botaniques de la Ville de Genève and South African National Biodiversity Institute, Pretoria, Available online: http://africanplantdatabase.ch (accessed on 28 November 2022).
- de Wilde, W.J.J.O. Lythraceae. In *Flora Malesiana. Series I Seed Plants*; De Wilde, W.J.J.O., Duyfjes, B.E.E., Eds.; Naturalis Biodiversity Center/Foundation Flora Malesiana: Leiden, The Netherlands, 2016; Volume 22, pp. 1–64.
- 12. PIER: US Forest Service, Pacific Island Ecosystems at Risk. Available online: http://www.hear.org.pier/ (accessed on 6 June 2022).
- Baret, S.; Rouget, M.; Richardson, D.M.; Lavergne, C.; Egoh, B.; Dupont, J.; Strasberg, D. Current distribution and potential extent of the most invasive alien plant species on La Réunion (Indian Ocean, Mascarene islands). *Austral. Ecology* 2006, *31*, 747– 758.

- 14. Jaworski, C.A.; Phatak, S.C. *Cuphea glutinosa* selections for flowering ornamental ground cover in southeast United States. In *Advances in New Crops*; Janick, J.; Simon, J.E., Eds; Timber Press: Portland, OR, USA, 1990; pp. 467–469.
- 15. Jaworski, C.A. Flowering ornamental Cuphea glutinosa 'Purple Passion' and 'Lavender Lei'. Hortscience 1992, 27, 940.
- Martínez-Bonfil, B.P.; Pineda-Montero, M.; López-Laredo, A.R.; Salecado-Morales, G.; Evangelista-Lozano, S.; Trejo-Tapia, G. A propagation procedure for *Cuphea aequipetala* Cav. (Lythraceae) and antioxidant properties of wild and greenhouse-grown plants. *Bol. Latinoam. Caribe. Plant. Med. Aromát.* 2013, 12, 1–14.
- 17. Rather, M.A.; Gupta, K.; Mandal, M. Inhibition of biofilm and quorum sensing-regulated virulence factors in *Pseudomonas aeru*ginosa by *Cuphea carthagenensis* (Jacq.) J.F.Macbr. leaf extract: An *in vitro* study. J. Ethnopharmacol. **2021**, 269, 113699.
- Garibay-Castro, L.R.; Gutiérrez-Yurrita, P.J.; López-Laredo, A.R.; Hernández-Ruíz, J.; Trejo-Espino, J.L. Potential distribution and medicinal uses of the Mexican plant *Cuphea aequipetala* Cav. (Lythraceae). *Diversity* 2022, 14, 403.
- Olejniczak, J. Cuphea. In Wild Crop Relatives: Genomic and Breeding Resources: Oilseeds; Kole, C., Ed.; Springer: Berlin/Heidelberg, Germany, 2011; pp. 117–136.
- 20. Ghebretinsae, A.G.; Graham, S.A.; Camilo, G.R.; Barber, J.C. Natural infraspecific variation in fatty acid composition of *Cuphea* (Lythraceae) seed oil. *Ind. Crops Prod.* **2008**, *27*, 279–287.
- 21. Floh, E.I.S.; Handro, W.; Rita, I. *Cuphea* species: Tissue culture, micropropagation and production of medium-chain fatty acids. In *Biotechnology in Agriculture and Forestry*; Bajaj, Y.P.S., Ed.; Springer GmbH: Berlin/Heidelberg, Germany, 1999; 43, pp. 78–84.
- Phippen, W.B. Cuphea. In Handbook of Plant Breeding; Vollmann, J., Rajcan, I., Eds.; Springer: Dordrecht, The Netherlands; Heidelberg, Germany; London, UK; New York, NY, USA, 2009; Volume 4, pp. 517–533.
- Abel, C.A.; Roekel, J.W.V.; Wilson. R.L. Cuphea lanceolata and Cuphea ignia seed increase using three pollinators in insect-proof cages in the field. Southwest. Entomol. 2019, 44, 95–98.
- 24. Hirsinger, F.; Knowles, P.F. Morphological and agronomic description of selected *Cuphea* germplasm. *Econom. Bot.* **1984**, *38*, 439–451.
- 25. Knapp, S.J.; Crane, J.M. Registration of reduced seed shattering Cuphea germplasm PSR23. Crop Sci. 2000, 40, 299–300.
- 26. Knothe, G.; Cermak, S.C.; Evangelista, R.L. *Cuphea* oil as source of biodiesel with improved fuel properties caused by high content of methyl decanoate. *Energy Fuels* **2009**, *23*, 1743–1747.
- Bergmeier, D.; Berres, P.H.D.; Filippi, D.; Bilibio, D.; Bettiol, V.R.; Priamo, W.L. Extraction of total polyphenols from hibiscus (*Hibiscus sabdariffa* L.) and waxweed/'sete-sangrias' (*Cuphea carthagenensis*) and evaluation of their antioxidant potential. *Acta Sci. Technol.* 2014, *36*, 545–551.
- Paxton, J. Cuphea melvilla. In Paxton's Magazine of Botany and Register of Flowering Plants; Orr,W.S. & Co.: London, UK, 1841; Volume 8, pp. 197–198.
- 29. Graham, S.A.; Cavalcanti, T.B. The yellow-flowered species of *Cuphea* (Lythraceae), including three new taxa. *Brittonia* **1999**, *51*, 24–30.
- Elgindi, M.R.; Ayoub, N.; Milad, R. A comprehensive review of *Cuphea* (Lythraceae). *Res. J. Pharm. Biol. Chem. Sci.* 2011, 2, 847– 855.
- Gesch, R.W.; Barbour, N.W.; Forcella, F.; Voorhees, W.B. Cuphea growth and development. Responses to temperature. In Trends in New Crops and New Uses; Janick, J.; Whipkey, A., Eds.; ASHS Press: Alexandria, VA, USA, 2002; pp. 213–215.
- 32. Gesch, R.W.; Forcella, F. Differential sensitivity to temperature of *Cuphea* vegetative and reproductive growth. *Ind. Crops Prod.* **2007**, *25*, 305–309.
- 33. Crane, J.; Miller, A.L.; Van Roekel, J.W.; Walters, C. Triacylglycerols determine the unusual storage physiology of *Cuphea* seed. *Planta* **2003**, *217*, 699–708.
- Graham, S.A.; Coelho-José, G.P.; Murad, A.M.; Rech, E.L.; Cavalcanti, T.B.; Inglis, P.W. Patterns of fatty acid composition in seed oils of *Cuphea*, with new records from Brazil and Mexico. *Ind. Crops Prod.* 2016, 87, 379–391.
- 35. Thompson, A.E.; Kleiman, R. Effect of seed maturity on seed oil and protein content of *Cuphea* species. *JAOCS* **1988**, *65*, 139–146.
- Forcella, F.; Gesch, R.W.; Isbell, T.A. Seed yield, oil, and fatty acids of *Cuphea* in the Northwestern Corn Belt. *Crop Ecol. Manag. Qual.* 2005, 45, 2195–2202.
- 37. Jaradat, A.A. Evolution of Cuphea PSR23 under cultivation. Euphytica 2016, 210, 41-55.
- 38. Eller, F.J.; Cermak, S.C.; Taylor, S.L. Supercritical carbon dioxide extraction of Cuphea seed oil. Ind. Crops Prod. 2011, 33, 554–557.
- 39. Evangelista, R.L.; Cermak, S.C. Full-press oil extraction of *Cuphea* (PSR23) seeds. J. Am. Oil Chem. Soc. 2007, 84, 1169–1175.
- 40. Evangelista, R.L.; Cermak, S.C.; Isbell, T.A. Dehulling of *Cuphea* PSR23 seeds to reduce color of the extracted oil. *Ind. Crops Prod.* **2010**, *31*, 437–443.
- 41. Phippen, W.B.; Isbell, T.A.; Phippen, M.E. Total seed oil and fatty acid methyl ester contents of *Cuphea* accessions. *Ind. Crops Prod.* **2006**, *24*, 52–59.
- 42. Wolf, R.B.; Graham, S.A.; Kleiman, R. Fatty acid composition of Cuphea seed oils. JACOS 1983, 60, 103–104.
- Hovoraková, P.; Laloučková, K.; Skřivanová, E. Determination of *in vitro* antibacterial activity of plant oils containing mediumchain fatty acids against Gram-positive pathogenic and gut commensal bacteria. *Czech J. Anim. Sci.* 2018, 63, 119–125.
- 44. Santos, M.C.; Henriques, A.T.; Mendez, A.S.L. Analytical methods of phytochemicals from the *Cuphea* genus—A review. *Drug Anal. Res.* **2021**, *5*, 4–10.
- Krepsky, P.B.; Isidório, R.G.; de Souza Filho, J.D.; Côrtes, S.F.; Castro Braga, F. Chemical composition and vasodilatation induced by *Cuphea carthagenensis* preparations. *Phytomedicine* 2012, 19, 953–957.

- Santos, M.C.; Farias, L.S.; Merlugo, L.; de Oliveira, T.V.; Barbosa, F.S.; Fuentefria, A.M.; Henriques, A.T.; Garcia, C.V.; Mendez, A.S.L. UPLC-MS for identification of quercetin derivatives in *Cuphea glutinosa* Cham. & Schltdl (Lythraceae) and evaluation of antifungal potential. *Curr. Pharm. Anal.* 2018, 14, 586–594.
- Sobolewska, D.; Owczarek, A.; Olszewska, M.; Paulino, N.; Podolak, I.; Paśko, P.; Wróbel-Biedrawa, D.; Michalska, K. UHPLC-PDA-ESI-MS profile of phenolic compounds in the aerial parts of *Cuphea ingrata* Cham. & Schltdl. *Nat. Prod. Res.* 2022, *36*, 3721–3725.
- 48. Elgindi, M.R.; Ayoub, N.; Milad, R.; Mekky, R. Antioxidant and cytotoxic activities of *Cuphea hyssopifolia* Kunth (Lythraceae) cultivated in Egypt. J. Pharmacogn. Phytochem. 2012, 1, 67–77.
- 49. Santos, D.Y.A.; Salatino, M.L.F.; Salatino, A. Flavonoids of species of *Cuphea* (Lythraceae) from Brazil. *Biochem. Sys. Ecol.* **1995**, 23, 99–103.
- Krepsky, P.B.; Farias, M.R.; Côrtes, S.F.; Castro Braga, F. Quercetin-3-sulfate: A chemical marker for Cuphea carthagenensis. Biochem. Sys. Ecol. 2010, 38, 125–127.
- 51. Wang, C.-C.; Chen, L.-G.; Yang, L.-L. Antitumor activity of four macrocyclic ellagitannins from *Cuphea hyssopifolia*. *Cancer Lett*. **1999**, *140*, 195–200.
- Ramírez-Atehortúa, A.M.; Morales-Agudelo, L.; Osorio, E.; Lara-Guzmán, O.J. The traditional medicinal plants *Cuphea calophylla*, *Tibouchina kingii*, and *Pseudoelephantopus spiralis* attenuate inflammatory and oxidative mediators. *Evid. Based Complement. Alternat. Med.* 2018, 1953726. doi: doi.org/10.1155/2018/1953726
- Cardenas-Sandoval, B.A.; López-Laredo, A.R.; Martínez-Bonfil, B.P.; Bermúdez-Torres, K.; Trejo-Tapia, G. Advances in the phytochemistry of *Cuphea aequipetala*, *C. aequipetala* var. *hispida* and *C. lanceolata*: Extraction and quantification of phenolic compounds and antioxidant activity. *Rev. Mex. Ing. Quím.* 2012, *11*, 401–413.
- 54. Ismail, W.M.; Ezzat, S.M.; Michel, H.E.; El Deeb, K.S.; El-Fishawy, A.M. Angiotensin converting enzyme and renin inhibition activities, antioxidant properties, phenolic and flavonoid contents of *Cuphea ignea* A. DC. *J. Rep. Pharm. Sci.* **2020**. *9*, 92–96.
- 55. Scio, E.; Mendes, R.F.; Motta, E.V.S.; Bellozi, P.M.Q.; Aragão, D.M.O.; Mello, J.; Fabri, R.L.; Moreira, J.R.; de Assis, I.V.L.; Bouzada M.L.M. Antimicrobial and antioxidant activities of some plant extracts. In *Phytochemicals as Nutraceuticals Global Approaches to Their Role in Nutrition and Health*; Rao, V., Ed.; InTech: London, UK, 2012; pp. 21–42.
- 56. Gonzalez, A.G.; Valencia, E.; Exposito, T.S.; Barrera, J.B.; Gupta, M.P. Chemical components of *Cuphea* species. Carthagenol: A new triterpene from *C. carthagenensis. Planta Med.* **1994**, *60*, 592–593.
- 57. Moustafa, E.S.; Swilam, N.F.; Ghanem, O.B.; Hashim, A.N.; Nawwar, M.A.; Lindequist, U.; Linscheid, M.W. A coumarin with an unusual structure from *Cuphea ignea*, its cytotoxicity and antioxidant activities. *Pharmazie* **2018**, *73*, 241–243.
- Mousa, A.M.; El-Sammad, N.M.; Hassan, S.K.; Madboli, A.E.N.A.; Hashim, A.N.; Moustafa, E.S.; Bakry, S.M.; Elsayed, E.A. Antiulcerogenic effect of *Cuphea ignea* extract against ethanol-induced gastric ulcer in rats. *BMC Complement. Altern. Med.* 2019, 19, 345.
- Santos, M.C.; Toson, N.S.B.; Pimentel, M.C.B.; Bordignon, S.A.; Mendez, A.S.; Henriques, A.T. Polyphenols composition from leaves of *Cuphea* spp. and inhibitor potential, *in vitro*, of angiotensin I-converting enzyme (ACE). *J. Ethnopharmacol.* 2020, 255, 112781.
- 60. Aguilar-Rodríguez, S.; Echeveste- Ramírez, N.L.; López-Villafranco, E.; Aguilar-Contreras, A.; Vega-Ávilla, E.; Reyes-Chilpa, R. Etnobotánica, micrografía analítica de hojas y tallos y fitoquimica de *Cuphea aequipetala* Cav. (Lythraceae): Una contribución a la Farmacopea Herbolaria de los Estados Unidos Mexicanos (FHEUM). *Bol. Latinoam. Caribe. Plantas Med. Aromát.* 2012, *11*, 316–330.
- 61. Martins, D.; Roque, N.F. Constituents of Cuphea aperta. Fitoterapia 1995, 66, 187.
- Klider, L.M.; Machado, C.D.; Almeida, V.P.; Tirloni, C.A.S.; Marques, A.A.M.; Palozi, R.A.C.; Lorençone, B.R.; Romão, P.V.M.; Guarnier, L.P.; Casserimo, N.S.; et al. *Cuphea calophylla* var. mesostemon (Koehne) S.A. Graham: A whole-ethnopharmacological investigation. *J. Med. Food* 2021, 24, 394–410.
- Zago, A.M.; Carvalho, F.B.; Gutierres, J.M.; Bohnert, C.; Fernandes, M.D.C.; Morandini, L.M.; Coelho, H.S.; Fogaça, A.O.; Andrade, C.M.; Mostardeiro, M.A.; et al. A phytochemical study of the *Cuphea glutinosa* from Southern Brazil: Na+,K+- ATPase activity inhibition and antioxidant properties. *Nat. Prod. Res.* 2019, *33*, 3426–3431.
- Mahmoud, D.B.; Ismail, W.M.; Moatasim, Y.; Kutkat, O.; ElMeshad, A.N.; Ezzat, S.M.; El Deeb, S.M.; El Deeb, K.S.; El-Fishawy, A.M.; Gomaa, M.R.; et al. Delineating a potent antiviral activity of *Cuphea ignea* extract loaded nano-formulation against SARS-CoV-2: In *silico* and *in vitro* studies. *J. Drug Deliv. Sci. Technol.* 2021, 66, 102845.
- 65. Meinhart, A.D.; Damin, F.M.; Caldeirão, L.; Godoy, H.T. Methylxanthines in 100 Brazilian herbs and infusions: Determination and consumption. *Emir. J. Food Agric*. **2019**, *31*, 125–133.
- 66. Santos, M.C.; Soares, K.D.; Beltrame, B.M.; Toson, N.S.; do Carmo, B.; Pimentel, M.; Bordignon, S.A.; Apel, M.A.; Mendez, A.S.L.; Henriques, A.T. Polyphenolic composition and *in vitro* anti-hypertensive and anti-inflammatory effects of *Cuphea lindmaniana* and *Cuphea urbaniana*. *Chem. Biodivers*. 2021, 18, e2100041.
- 67. Lechner, M.; Reiter, B.; Lorbeer, E. 1999. Determination of free and esterified sterols in potential new oil seed crops by coupled on-line liquid chromatography-gas-chromatography. *Lipid/Fett* **1999**, *101*, 171–177.
- 68. Calzada, F.; Alanís, A.D.; Meckes, M.; Tapia-Contreras, A.; Cedillo-Rivera, R. *In vitro* susceptibility of *Entamoeba histolytica* and *Giardia lamblia* to some medicinal plants used by the people of Southern Mexico. *Phytother. Res.* **1998**, *12*, 70–72.
- 69. Calzada, F. Additional antiprotozoal constituents from *Cuphea pinetorum*, a plant used in Mayan traditional medicine to treat diarrhoea. *Phytother. Res.* 2005, 19, 725–727.

- 70. Perez-Castorena, A.L.; Maldonado, E. Triterpenes and flavonoid glycosides from *Cuphea wrightii*. *Biochem. Syst. Ecol.* **2003**, *31*, 331–334.
- 71. Elisabetsky, E.; Addison Posey, D. Use of contraceptive and related plants by the Kayapo Indians (Brazil). *J. Ethnopharmacol.* **1989**, *26*, 299–316.
- Alvarado, T.D.; Mariezcurrena Berasain, M.D.; Salem, A.Z.M.; Pinzón Martínez, D.L. Antimicrobial and antioxidant activities of two medicinal plants *Cuphea aequipetala* var. *hispida* (Cav.) Koehne and *Eryngium comosum* Delaroche F against bacteria related to equine infections. *J. Equine Vet. Sci.* 2020, *94*, 103269.
- 73. Garcia, D.; Domingues, M.V.; Rodrigues, E. Ethnopharmacological survey among migrants living in the Southeast Atlantic Forest of Diadema, São Paulo, Brazil. *J. Ethnobiol. Ethnomed.* **2010**, *6*, 29.
- 74. Castillo-Juárez, I.; González, V.; Jaime-Aguilar, H.; Martinez, G.; Linares, E.; Bye, R.; Romero, I. Anti-*Helicobacter pylori* activity of plants used in Mexican traditional medicine for gastrointestinal disorders. *J. Ethnopharmacol.* **2009**, *122*, 402–405.
- 75. Amat, A.G.; Yajia, M.E.; Gonzalez, C.F.; Lorca, G.L.; Sanchez Gonzalez, F.; Riglos, A.G.; Veron, J.R. Evaluation of cytological parameters induced by aqueous extracts of seven plants used as anti-hypertensive agents in Argentine folk medicine. *Acta Farm. Bonaerense* **2002**, *21*, 37–42.
- 76. Menetrier, J.V.; Bonkoski, V.R.; Medeiros, K.A.; Estevan, D.A.; Palozi, R.A.C.; Livero, F.A.D.R.; Velasquez, L.G.; Lourenço, E.L.B.; Gasparotto Junior, A. Ethnomedicinal plants used for the treatment of cardiovascular diseases by healers in the southwestren state of Paraná, Brazil, and their validation based on scientific pharmacological data. J. Relig. Health. 2020, 59, 3004–3036.
- 77. Ribeiro, R.V.; Bieski, I.G.C.; Balogun, S.O.; Martins, D.T.O. Ethnobotanical study of medicinal plants used by Ribeirinhos in the North Araguaia microregion, Mato Grosso, Brazil. *J. Ethnopharmacol.* **2017**, *205*, 69–102.
- 78. Sauini, T.; Stern da Fonseca-Kruel, V.; Baptistela Yazbek, P.; Matta, P.; Cassas, F.; da Cruz, C.; Hortal Pereira Barretto, E.; Santos, M.A.; Silva Gomez, M.A.; Francischetti Garcia, R.J.; et al. Participatory methods on the recording of traditional knowledge about medicinal plants in Atlantic forest, Ubatuba, São Paulo, Brazil. *PLoS ONE* **2020**, *15*, e0232288.
- 79. Castro Braga, F.; Wagner, H.; Lombardi, J.A.; de Oliveira, A.B. Screening the Brazilian flora for anti-hypertensive plant species for *in vitro* angiotensin-I-converting enzyme inhibiting activity. *Phytomedicine* **2000**, *7*, 245–250.
- 80. DeFilipps, R.A.; Crepin, J.; Maina, S.L. *Medicinal plants of the Guianas (Guyana, Surinam, French Guiana)*; Department of Botany, National Museum of Natural History, Smithsonian Institution: Washington, DC, USA, 2004; p. 165.
- Vendruscolo, G.S.; Mentz, L.A. Estudo da concordância das citações de uso e importância das espécies e famílias utilizadas como medicinais pela comunidade do bairro Ponta Grossa, Porto Alegre, RS, Brasil. Acta Bot. Bras. 2006, 20, 367–382.
- 82. Gupta, M.P.; Solís, P.N.; Calderón, A.I.; Guinneau-Sinclair, F.; Correa, M.; Galdames, C.; Guerra, C.; Espinosa, A.; Alvenda, G.I.; Robles, G.; et al. Medical ethnobotany of the Teribes of Bocas del Toro, Panama. *J. Ethnopharmacol.* **2005**, *96*, 389–401.
- 83. Kujawska, M.; Schmeda-Hirschmann, G. The use of medicinal plants by Paraguayan migrants in the Atlantic Forest of Misiones, Argentina, is based on Guaraní tradition, colonial and current plant knowledge. J. Ethnopharmacol. 2022, 283, 114702.
- 84. Rahmatullah, M.; Ferdausi, D.; Mollik, M.A.H.; Jahan, R.; Chowdhury, M.H.; Haque, W.M. A survey of medicinal plants used by Kavirajes of Chalna Area, Khulna District, Bangladesh. *Afr. J. Trad. Complement. Altern. Med.* **2010**, *7*, 91–97.
- 85. Bolson, M.; Hefler, S.R.; Dall'Oglio Chavez, E.I.; Gasparotto Junior, A.; Cardozo Junior, E.L. Ethno-medicinal study of plants used for treatment of human ailments, with residents of the surrounding region of forest fragments of Paraná, Brazil. *J. Ethnopharmacol.* **2015**, 161, 1–10.
- 86. Basualdo, I.; Zardini, E.; Ortiz, M. Medicinal plants of Paraguay: Underground organs. Econ. Bot. 1991, 45, 86–96.
- Pavetti, C.; Basualdo, I.; Ortiz, M.; Soria, N. Plantas nativas de uso en medicina popular en el Paraguay. Parte III. *Acta Amazon*. 1988, 18, 39–48.
- 88. Lentz, D. Medicinal and other economic plants of the Paya of Honduras. Econ. Bot. 1993, 47, 358–370.
- 89. Aquino, A.M. "Living with joy": History, sociability, and alterity in Kaingang ritual life. *Vibrant* **2021**, *18*, e18505.
- 90. Queiroz, I.B.; Lino, J.T. Kaingang's Kiki ritual: Material culture of an indigenous religious ritual in Southern Brazil. *R. Museu. Arq. Etn.* **2021**, *36*, 46–58.
- Alonso-Castro, A.J.; Arana-Argáez, V.; Yáñez-Barrientos, E.; Ramirez-Camacho, M.A.; Wrobel, K.; Torres-Romero, J.C.; León-Callejas, C.; Wrobel, K. Antinociceptive and anti-inflammatory effects of *Cuphea aequipetala* Cav (Lythraceae). *Inflammopharma-cology* 2021, 29, 295–306.
- 92. Villa-Ruano, N.; Zurita-Vásquez, G.G.; Pacheco-Hernández, Y.; Betancourt-Jiménez, M.G.; Cruz-Durán, R.; Duque-Bautista, H. Anti-lipase and antioxidant properties of 30 medicinal plants used in Oaxaca, México. *Biol. Res.* **2013**, *46*, 153–160.
- Waizel-Bucay, J.; Martinez-Porcayo, G.; Villareal-Ortega, M.L.; Alonso-Cortés, D.; Pliego-Castañeda, A. Estudio preliminar etnobotánico, fitoquímico, de la actividad citotóxica y antimicrobiana de *Cuphea aequipetala* Cav. (Lythraceae). *Polibotánica* 2003, 15, 99–108.
- 94. Palacios-Espinosa, J.F.; Arroyo-García, O.; García-Valencia, G.; Linares, E.; Bye, R.; Romero, I. Evidence of the anti-*Helicobacter pylori*, gastroprotective and anti-inflammatory activities of *Cuphea aequipetala* infusion. *J. Ethnopharmacol.* **2014**, *151*, 990–998.
- 95. Baracho, N.C.V.; Brügger, P.G.; Camanducaia, D.S.M.; Sanches, A.I.F.; Sanches, R.S. Effects of chronic treatment with aqueous extract of *Cuphea balsamona* L. on the lipid profile of rats submitted to a high-cholesterol diet. In Proceedings of the Congresso Brasileiro de Farmacologia e Terapêutica Experimental, Ribeirão Preto, SP, Brasil, 18–21 October 2010; p. 42
- 96. Santos, M.C.; Soares, K.D.; Beltrame, B.M.; Bordignon, S.A.; Apel, M.A.; Mendez, A.S.; Henriques, A.T. *Cuphea* ssp.: Antichemotactic study for a potential anti-inflammatory drug. *Nat. Prod. Res.* **2021**, *35*, 6058–6061.

- Lima Prando, T.B.; Barboza, L.N.; Gasparotto, F.M.; Araújo Vde, O.; Slgnor Tirloni, C.A.; de Souza, L.M.; Lourenço, E.L.; Gasparotto Junior, A. Ethnopharmacological investigation of the diuretic and hemodynamic properties of native species of the Brazilian biodiversity. J. Ethnopharmacol. 2015, 174, 369–378.
- Fernandes, F.R.; Santos, A.L.; Arruda, A.M.S.; Vasques-Pinto, L.M.C.; Godinho, R.O.; Torres, L.M.B.; Lapa, A.J.; Souccar, C. Antinociceptive and anti-inflammatory activities of the aqueous extract and isolated *Cuphea carthagenensis* (Jacq.)J.F.Macbr. *Rev. Bras. Farmacogn.* 2002, *12*, 55–56.
- Barboza, L.N.; Livero, F.A.; Prando, T.B.; Ribeiro R.C.; Lourenço, E.L.; Budel, J.M.; de Souza, L.M.; Acco, A.; Dalsenter, P.R.; Gasparotto, A. Junior. Atheroprotective effects of *Cuphea carthagenensis* (Jacq.)J.F.Macbr. in New Zealand rabbits fed with cholesterol-rich diet. *J. Ethnopharmacol.* 2016, 187, 134–145.
- Biavatti, M.W.; Farias, C.; Curtius, F.; Brasil, L.M.; Hort, S.; Leite, S.N.; Prado, S.R.T.; Preliminary studies on *Campomanesia xan-thocarpa* (Berg.) and *Cuphea carthagenensis* (Jacq.)J.F.Macbr. aqueous extract: Weight control and biochemical parameters. *J. Ethnopharmacol.* 2004, 93, 385–389.
- Schuldt, E.Z.; Ckless, K.; Simas, M.E.; Farias, M.R.; Ribeiro-Do-Valle, R.M. Butanolic fraction from *Cuphea carthagenensis* Jacq McBride relaxes rat thoracic aorta through endothelium-dependent and endothelium-independent mechanisms. *J. Cardiovasc. Pharmacol.* 2000, 35, 234–239.
- 102. Schaedler Schuldt, M.I.; Palozi, R.A.C.; Tirloni, C.A.S.; Silva, A.O.; de Oliveira Araújo, V.; Lourenço, E.L.B.; Souza, L.M.;Lívero, F.A.R.; Junior, A.G. Redox regulation and NO/cGMP plus K+ channel activation contributes to cardiorenal protection induced by *Cuphea carthagenensis* (Jacq.) J.F.Macbr. in ovariectomized hypertensive rats. *Phytomedicine* 2018, *51*, 7–19.
- Schuldt, E.Z.; Farias, M.R.; Ribeiro-do-Valle, R.M.; Ckless, K. Comparative study of radical scavenger activities of crude extract and fractions from *Cuphea carthagenesis* leaves. *Phytomedicine* 2004, 11, 523–529.
- 104. Moke, E.G.; Mordi, J.C.; Umukoro, E.K. Effects of methanol leaf extract of *Cuphea hyssopifolia* Kunth on liver enzymes activity and antioxidant indices of paracetamol-induced hepatotoxicity in Wistar rats. *Afr. J. Biomed. Res.* 2020, 23, 123–126.
- 105. Hassan, S.K.; Mousa, A.M.; El-Sammad, N.M.; Abdel-Halim, A.H.; Khalil, W.K.B.; Elsayed, E.A.; Anwar, N.; Linscheid, M.W.; Moustafa, E.S.; Hashim, A.N.; et al. Antitumor activity of *Cuphea ignea* extract against benzo(a)pyrene-induced lung tumorigenesis in Swiss Albino mice. *Toxicol. Rep.* 2019, 6, 1071–1085.
- Ismail, W.M. A pharmacognostical study of *Cuphea ignea* A.DC. family: Lythraceae, cultivated in Egypt. CU Theses 2020 [Doctoral dissertation, Cairo University]. 2020. https://docslib.org/doc/4536313/Cuphea-ignea-a.
- 107. Carvalho Siqueira, M.; Stutz, E.T.G.; Silva, T.C.; Carvalho Alves, J.N. Evaluation of the hypocholesterolemic effect of *Cuphea ingrata* Cham.& Schltdl. in mice induced to hypercholesterolemia. *Braz. J. Develop.* **2020**, *6*, 60518–60531.
- 108. Sülsen, V.; Güida, C.; Coussio, J.; Paveto, C.; Muschetti, L.; Martino, V. *In vitro* evaluation of trypanocidal activity in plants used in Argentine traditional medicine. *Parasitol. Res.* **2006**, *98*, 370–374.
- Barbosa, E.; Calzada, F.; Campos, R. *In vivo* antigiardial activity of three flavonoids isolated of some medicinal plants used in Mexican traditional medicine for the treatment of diarrhea. *J. Ethnopharmacol.* 2007, 109, 552–554.
- 110. Meckes, M.; Villarreal, M.L.; Tortoriello, J. A microbiological evaluation of medicinal plants used by the Maya people of Southern Mexico. *Phytother. Res.* **1995**, *9*, 244–250.
- Otenio, J.K.; Baisch, R.G.; Poplawski Carneiro, V.P.; Botelho Lourenço, E.L.; Alberton, O.; Soares, A.A.; Boleta Ceranto, D.C.F.; Jacomassi, E. Etnofarmacologia da *Cuphea carthagenensis* (Jacq.) J. F. Macbr: Uma revisão. *Braz. J. Dev.* 2020, 6, 10206–10219.
- 112. Das, A.; Chaudary, S.K.; Bhat, H.R.; Shakya, A. *Cuphea carthagenensis*: A review of its ethnobotany, pharmacology and phytochemistry. *Bull Arunachal Res.* 2018, 33, 1–14.
- 113. Ataabadi, E.A.; Golshiri, K.; Jüttner, A.; Krenning, G.; Danser, A.H.J.; Roks, A.J.M. Nitric oxide-cGMP signaling in hypertension.Current and future options for pharmacotherapy. *Hypertension* **2020**, *76*, 1055–1068.
- Guerrero, L.; Castillo, J.; Quiñones, M.; Garcia-Vallvé, S.; Arola, L.; Pejuadas, G.; Muguerza, B. Inhibition of angiotensin-converting enzyme activity by flavonoids: Structure-activity relationship studies. *PLoS ONE* 2012, 7, e49493.
- 115. Graham, S.A. Revision of Cuphea sect. Leptocalyx (Lythraceae). Sys. Bot. 1989, 14, 43-76.
- 116. Toson, N.; Santos, M.C.; Fasolo, J.A.; Rico, E.P.; Vendruscolo, M.H.; Mendez, A.; Henriques, A. Evaluation of neuroinflammatory cytokine production in miquelianin isolated from *Cuphea glutinosa* in adult zebrafish. In Proceedings of the 7th Brazilian Conference on Natural Product/ XXXIII RESEM Proceedings, Rio de Janeiro, RJ, Brasil, 10-13 November 2019; Volume 1, p. 117742.
- 117. Campana, P.R.V.; Mansur, D.S.; Gusman, G.S.; Ferreira, D.; Teixeira, M.M.; Castro Braga, F.; Anti TNF-α activity of Brazilian medicinal plants and compounds from *Ouratea semiserrata*. *Phytother. Res.* **2015**, *29*, 1509–1515.
- 118. Gusman, G.S.; Campana, P.R.V.; Castro, L.C.; Castilho, R.O.; Teixeira, M.M.; Castro Braga, F. Evaluation of the effects of some Brazilian medicinal plants on the production of TNF-α and CCL2 by THP-1 cells. *Evid. Based Complement. Alternat. Med.* 2015, 497123. doi: 10.1155/2015/497123
- 119. Madboli, A.-N.A.; Mousa, A.M.; El-Sammad, N.M.; Hassan, S.K; Nawwar, M.; Seif, M. *Cuphea ignea* extract relieved the histological changes and activated the NF-κB protein of female reproductive organs and stomach in Et-OH-treated rats. *Egypt. J. Chem.* 2023, *Online ahead of print*. https://doi.org/10.21608/ejchem.2023.161329.6934.
- 120. Botsaris, A.S. Plants used traditionally to treat malaria in Brazil: The archives of Flora Medicinal. *J. Ethnobiol. Ethnomed.* **2007**, *3*, 18.
- Bussmann, R.W.; Paniagua Zambrana, N.Y.; Romero, C.; Hart, R.E. Astonishing diversity—the medicinal plant markets of Bogotá, Colombia. J. Ethnobiol. Ethnomed. 2018, 14, 43.

- 122. Rather, M.A.; Deori, P.J., Gupta, K.; Daimary, N.; Deka, D.; Quershi, A.; Dutta, T.K.; Joardar, S.N.; Mandal, M. Ecofriendly phytofabrication of silver nanoparticles using aqueous extract of *Cuphea carthagenensis* and their antioxidant potential and anti-bacterial activity against clinically important human pathogens. *Chemosphere* **2022**, *300*, 134497.
- 123. González-Pedroza, M.G.; Benítez, A.R.T., Navarro-Marchal, S.A.; Martínez-Martínez, E.; Marchal, J.A.; Boulaiz, H.; Morales-Luckie, R. Biogeneration of silver nanoparticles from *Cuphea procumbens* for biomedical and environmental applications. *Sci. Rep.* 2023, 13, 790.
- 124. Andrighetti-Fröhner, C.R.; Sincero, T.C.M.; Da Silva, A.C.; Savi, L.A.; Gaido, C.M.; Bettega, J.M.R.; Mancini, M.; De Almeida, M.T.R.; Barbosa, R.A.; Farais, M.R.; et al. Antiviral evaluation of plants from Brazilian Atlantic Tropical Forest. *Fitoterapia* 2005, 76, 374–378.
- 125. Chen, L.-G.; Yen, K.-Y.; Yang, L.-L.; Hatano, T.; Okuda, T.; Yoshida, T. Macrocyclic ellagitannin dimers, cuphiins D1 and D2, and accompanying tannins from *Cuphea hyssopifolia*. *Phytochemistry* **1999**, *50*, 307–312.
- 126. Kinjo, J.; Nakano, D.; Fujioka, T.; Okabe, H. Screening of promising chemotherapeutic candidates from plants extracts. *J. Nat. Med.* **2016**, *70*, 335–360.
- 127. Sobolewska, D.; Galanty, A.; Granica, S.; Podolak, I.; Olszewska, M.A.; Owczarek, A.; Paulino, N.; Michalska, K. *In vitro* cytotoxic activity of *Cuphea ingrata* Cham. & Schltdl. extracts related to the oenothein B content. *Nat. Prod. Res.* 2022. 1–5. https://doi.org/10.1080/14786419.2022.2103699. Online ahead of print.
- 128. Uscanga-Palomeque, A.C.; Zapata-Benavides, P.; Saavedra-Alonso, S.; Zamora-Ávila, D.E.; Franco-Molina, M.A.; Arellano-Rodríguez, M.; Manilla-Muñoz, E.; Martínez-Torres, A.C.; Trejo-Ávila, L.M.; Rodríguez-Padilla, C. Inhibitory effect of *Cuphea aequipetala* extracts on murine B16F10 melanoma *in vitro* and *in vivo*. *BioMed. Res. Int.* 2019, 8560527.
- 129. Avila, E.V.; Aguilar, R.T.; Estrada, M.J.; Ortega, M.L.; Ramos, R.R. Cytotoxic activity of *Cuphea aequipetala*. *Proc. West. Pharmacol. Soc.* **2004**, *47*, 129–133.
- 130. Calleros, F.G.; Gomez, H.M.; Gonzales, L.A.; Zavala, S.M.A. Evaluation of the cytotoxic effect of extracts of *Cuphea aequipetala* Cav. and *Verbena carolina* L. on cancer cell lines. *Nat. Prod. Chem. Res.* **2018**, *6*, 79.
- 131. Wang, C.-C.; Chen, L.-G.; Yang, L.-L. Cuphiin D1, the macrocyclic hydrolyzable tannin induced apoptosis in HL-60 cell line. *Cancer Lett.* **2000**, *149*, 77–83.
- Husain, I.; Dale, O.R.; Martin, K.; Gurley, B.J.; Adams, S.J.; Avula, B.; Chittiboyina, A.G.; Khan, I.A.; Khan, S.I. Screening of medicinal plants for possible herb-drug interactions through modulating nuclear receptors, drug-metabolizing enzymes and transporters. J. Etnopharmacol. 2023, 301, 115822. https://doi.org/10.1016/j.jep.2022.115822.
- 133. Golonko, A.; Olichwier, A.J.; Swislocka, R.; Szczerbinski, L.; Lewandowski, W. Why do dietary flavonoids have a promising effect as enhancer of anthracyclines? Hydroxyl substituents, bioavailability and biological activity. *Int. J. Mol. Sci.* 2023, 24, 39.
- 134. Berti, M.T.; Gesch, R.W. Cuphea production and management. In *Industrial Crops, Handbook of Plant Breeding*; Cruz, V.M.V., Dierig, D.A., Eds; Springer Science + Business Media: New York, NY, USA, 2015; pp. 291–313.
- 135. Jackson, M.A.; Evans, K.O.; Price, N.P.J.; Blackburn, J.A.; Ward, C.J.; Ray, K.J.; Vermillion, K.E. New family of surfactants from biobased materials. *ACS Sustain. Chem. Eng.* **2021**,*9*,13842–13850.
- 136. Cermak, S.C.; Evangelista, R.L.; Jackson, M.A.; Compton, D.L.; Knothe, G.; Laszlo, J.A.; Evans, K.O. Biobased lubricants and functional products from *Cuphea* oil. In *Surfactants in Tribology*; Biresaw, G., Mittal, K.L., Eds; CRC Press: Boca Raton, FL, USA; Taylor & Francis Group: Boca Raton, FL, USA, 2015; pp. 443–482.
- 137. Cermak, S.C.; Isbell, T.A. Synthesis and physical properties of Cuphea-oleic estolides and esters. JAOCS 2004, 81, 297–303.
- 138. Isbell, T.A. US effort in the development of new crops (Lesquerella, Pennycress Coriander and Cuphea). OCL 2009, 4, 205–210.
- 139. Tisserat, B.; O'kuru, R.H.; Cermak, S.C.; Evangelista, R.L.; Doll, K.M. Potential uses for *Cuphea* oil processing byproducts and processed oils. *Ind. Crops Prod.* **2012**, *35*, 111–120.
- 140. Tao, L.; Milbrandt, A.; Zhang, Y.; Wang, W.-C. Techno-economic and resources analysis of hydroprocessed renewable jet fuel. *Biotechnol. Biofuels* **2017**, *10*, 261.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.